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Chapter 1 
During the 1950's the National Cancer Institute (NCI) started a screening 
program of natural products. Among the thousands of plants analyzed, campto· 
thecin, a plant alkaloid extract from the Camptotheca acuminata, an oriental tree 
which is cultivated throughout Asia, was found to be active against L 1210 
murine leukemia (1). In the early 1970's camptothecin underwent clinical 
testing. Although antitumor activity was observed in patients with colorectal 
cancer, melanoma and non-small-cell lung cancer further clinical development 
was precluded because of severe and unpredictable toxicities including, myelo-
suppression, diarrhea and hemorrhagic cystitis (2-5). In the mid 1980's several 
developments renewed the interest in camptothecin. Firstly, Hsiang et al. (6,7) 
identified topoisomerase I as the specific intracellular target of camptothecin. 
Secondly, overexpressed topoisomerase I level was found in advanced stages of 
human colon adenocarcinoma and other malignancies but not in normal tissue 
(8,9). This resulted in the development of several semisynthetic camptothecin 
analogues with more predictable toxicity profiles and consistent antitumor 
activity. One of these analogues is topotecan (SKF 104864, NSC 609699, (s)-9-
dimethylaminomethyl-10-hydroxycamptothecin, Hycamtin®) which in preclinical 
studies demonstrated broad spectrum antitumor activity (10,11). Phase I studies 
revealed that topotecan was very well tolerated with generally a brief and non-
cumulative neutropenia being the dose-limiting toxicity on all schedules (12,13). 
Major responses were observed in carcinomas of the ovary, lung (both small and 
non-small), oesophagus and colon. Phase II studies were initiated with a daily x5 
schedule based on the fact that most objective responses in phase I studies 
were observed with this schedule. 
This thesis includes clinical and pharmacological studies on topotecan which 
was focused towards the efficacy of the daily x5 schedule in patients with 
colorectal and ovarian cancer and towards the concept of prolonged exposure to 
the drug. 
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INTRODUCTION 
Camptothecin is a plant alkaloid extract from the Camptotheca acuminata tree, 
which is cultivated throughout Asia (1). In the early 1970's camptothecin 
demonstrated objective antineoplastic activity against gastrointestinal adeno-
carcinoma, melanoma, non-small cell lung cancer and acute myelocytic leukemia 
(2,3). However, further clinical development of camptothecin was hampered 
because of unpredictable toxicity, notably severe myelosuppression, 
hemorrhagic cystitis and severe diarrhea (3-5). At the same point in time it was 
shown that camptothecin is a strong inhibitor of the DNA and RNA synthesis (6-
9), while more recent studies revealed that camptothecin only induced single 
strand DNA-breaks in the presence of topoisomerase I, thus identifying this 
enzyme as a major target for the drug (10). 
Topoisomerases are essential nuclear enzymes that function to resolve 
topological problems in DNA. Two major topoisomerases, type I, (which 
produces single strand breaks), and II, (which produces double strand breaks), 
have been identified in all eukaryotic cells. Topoisomerase I is a monomeric 100 
kDa polypeptide encoded by a single copy gene located on chromosome 20q 12-
13.2 (11-13). Like all topoisomerases, topoisomerase I relaxes torsionally 
strained (supercoiled) duplex DNA so that replication and transcription can 
proceed. This is accomplished by forming a covalent adduct between topoiso-
merase I and DNA, termed the cleavable complex. This catalytic intermediate 
induces a single strand nick in the phosphodiester backbone of DNA, allowing 
the intact strand to pass through the nick (figure 1). DNA relaxation results from 
swivelling at this nick and so plays an important role in DNA replication and 
RNA transcription. The enzyme-bridged breaks are then resealed by topoisome-
rase I (relegation). 
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5' 3' 
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0----------~ .. - - - - -1-.------3' 5' 5' 3' 
Figure 1: 
Topoisomerase I becomes covalent bound to DNA, creating a DNA protein 
crosslink and a nick in the phosphodiester backbone. DNA relaxation results 
from swivelling at this nick. 
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Camptothecin inhibits topoisomerase I by stabilizing cleavable complexes 
resulting in single strand DNA breaks that cannot be relegated in the presence of 
the drug (14-19). Inhibition of RNA synthesis in cells is consistent with the 
enrichment of topoisomerase I on active transcription units (20-22) and the 
observation that topoisomerase I cleavable complexes occur preferentially within 
expressed genes (23-25). The reversibility of RNA synthesis inhibition that rapid-
ly occurs following removal of camptothecin from cultured cells is probably due 
to the dissociation of topoisomerase I cleavable complexes from transcription 
units (25). Immunological studies have demonstrated that topoisomerase I is 
concentrated in vivo in areas of active transcription by RNA polymerases 
(20,22). This may indicate that the camptothecin altered cleavable complexes 
block elongation by impeding the progression of RNA polymerase molecules 
along the transcription unit. 
DNA synthesis inhibition, although reversible following camptothecin exposure 
of short duration progressively becomes irreversible with increasing exposure 
duration (26). A specific mechanism for DNA synthesis inhibition has been 
suggested from an analysis of viral replication that accumulates in camptothecin 
treated cells (27-29). The analysis of these SV 40 replication intermediates has 
shown that strand breaks occur preferentially at replication forks (28). In 
presence of camptothecin, DNA synthesis is arrested, presumably due to collisi-
on between the replication fork and the drugtrapped cleavable complex resulting 
in formation of double strand DNA breaks (figure 2) (31). Recent studies have 
provided strong experimental evidence supporting this hypothesis. Halting the 
replication forks with aphidicolin, an inhibitor of DNA polymerase a and p, was 
shown to protect S-phase L1210 cells from camptothecin cytotoxicity without 
affecting cellular levels of cleavable complexes (32). 
The cytotoxicity of camptothecin mainly occurs in the S-phase (9,33,34). Cells 
in S-phase are as much as 1000 fold more sensitive to the cytotoxic effects of 
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3' 
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Fork arrest 
! 
Cell death 
Figure 2: 
Camptothecin and its binding site are represented. DNA synthesis is arrested by 
interaction of the drugtrapped cleavable complex with the advancing replication 
fork resulting in a fork breakage which is responsible for cell death. 
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camptothecin than cells in the G1-or G2-phase at time of brief exposure to the 
drug (33,35). This also suggests that cytotoxicity occurs from an interaction of 
cleavable complexes with the replication forks. There is also evidence that the 
regulation of topoisomerase I is altered in neoplastic cells. For example colon 
cancer cells contain a fivefold higher level of topoisomerase I than normal 
adjacent mucosal cells (36). So with inhibition of topoisomerase I some degree 
of selectivity might be expected. Besides, topoisomerase I is present in relatively 
high levels in both proliferating and quiescent cells suggesting that its function 
may be independent of cellular growth rate and thus topoisomerase I inhibitors 
may be active in slowly as well in rapidly proliferating tumors (37,38). 
With the increasing knowledge of function and inhibition of topoisomerase I a 
renewed interest in camptothecin occurred leading to the development of 
semisynthetic analogues with more predictable toxicity profiles and consistent 
antitumor activity. The two main analogues that have underwent clinical testing 
are topotecan and CPT-11 and these drugs will be discussed in more detail. 
TOPOTECAN 
Clinical pharmacology: 
Topotecan (SKF 104864), ((S)-9-dimethylaminomethyl-10-hydroxycamptothecin 
hydrochloride] is a semisynthetic analog of camptothecin with improved water 
solubility (figure 3). It incorporates a stable basic side chain at the 9-position of 
the A-ring of 10-hydroxycamptothecin, which provides water solubility at acid 
pH. Like camptothecin, topotecan undergoes a pH dependent reversible 
hydrolysis of the E-ring lactone, yielding an a, P dihydroxycarboxylic acid (figure 
4). Only the lactone form of the drug, which is the predominant form of the 
agent in an acid environment is biochemically and pharmacologically active 
(39,40). For example at a pH level of 6.0 the closed lactone form accounts for 
more than 80% of the total compound. With high performance liquid chromatographic 
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Rl R2 R3 
CPr H H H 
TPr OH (CH3),NHCH, H 
0-0-4:_ CPr· 11 H C2 HS 
SN·38 OH H C~H5 
Figure 3: 
Structure of camptothecin, topotecan, CPT·11 and SN·38. 
lIO 
-
-
OH 
Figure 4: 
Structure of topotecan lactone and the hydroxy acid form. 
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(HPLC) assay according to Beynen et al. (41) it is possible to differentiate between 
the closed lactone and the open hydroxy acid form. 
Studies to examine the equilibrium of the lactone and the hydroxy acid form revealed 
that in physiologic saline the lactone is converted to the hydroxy acid in a substantial 
amount, while the relatively low pH of dextrose 5% solutions (pH 4.5) slows down 
this process. Hydrolysis of the lactone to the hydroxy acid form in dextrose 5% soluti-
ons occurs slowly, with a halflife of 30 minutes with a maximal conversion of 
approximately 10% (42,43). The difference in the pH of the diluents for topotecan, 
and the duration between dilution and the drug administration is therefore obviously 
critical. Formulations that ensure consistent delivery of the lactone form need to 
be explored (42). 
In vivo topotecan is also rapidly converted to the open hydroxy acid form. At the 
end of a short infusion 50% of the total drug is present as the hydroxy acid form 
(43,44,45). Clinical pharmacology studies have attempted to measure both forms 
of the drug. Table 1 summarizes the reported results of the pharmacokinetics of topote-
can. 
Both the closed lactone form as well as the open hydroxy acid form of the agent 
are eliminated in a biexponential manner. The mean clearance of the lactone from 
the plasma is 27.0 literslhlm' (range 10.8-132 Llh/m'), with a mean elimination half 
life time of 3.0 h. (range 1.2-4.9 h). Renal elimination appears to be a major route 
of excretion fortopotecan with approximately 45% (range 39-80%) of the total drug 
excreted in the urine over 24 hours (42-53). 
Several phase I studies have examined a possible relation between toxic effects of 
topotecan and pharmacokinetics of the drug. A linear relationship has been described 
between the grade of leucopenia and the peak plasma concentration or the area under 
the concentration-time curve (AUG) of the lactone form of topotecan after a single 
30 minute infusion (44), In patients treated with topotecan at a daily 30 minute infusion 
during 5 days the relationship between the dose and the magnitude of topotecan 
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Schedule 
30 min. every 3 weeks 
30 min. daily x 5 every 3 weeks 
24 hr. infusion weekly' 
30 min. daily x 5 every 3 weeks. 
24 hr. infusion every 3 weeks" 
30 min. daily x 5 every 3 weeks 
30 min. one time 
30 min. daily x 5 every 3 weeks 
72 hr. continuous infusion 
Total topotecan 
Pediatric study 
nM 
.. 
TABLE 1: PHARMACOKINETICS OF TOPOTECAN 
Ref. t Yo (h) Peak lactone conc. ng/ml Clearance 
(dose mg/m2 per day) (L/h/m2) 
45 3.4 130 - 581 25.7 
(2.5 - 22.5) 
43 3.0 20.6·50.8 132 
(0.5 - 2.5) 
46 4.9 7.0 10.8 
(1.5) 
47 1.7 . 124 
48 2.9 6.4 - 30.7'" 28.3 
(2.0·7.5) 
49 2.7 36.9-79.8'" 31.8 
44 3.4 117·674 25.7 
(2.5 - 22.5) 
42 1.2 21·80'" 73.2 
(0.5· 2.5) 
50 3.0 1.7·3.6 20.9 
(0.75·1.9) 
Vd ss 24 h urine % dose 
(L/m2) 
76.4 40 
25.6 39 
61 -
186 80 
. 
-
86.1 20 
76.4 40 
26 30 
21.6 41.6 
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induced neutropenia is characterized by a sigmoidal Em" model (42,43). This relation 
suggests that although the hydroxy acid form of topotecan is significantly less cytotoxic 
than the lactone form it may still contribute to the myelosuppressive effects of 
topotecan. 
Preclinical studies: 
Topotecan has impressive antitumor activity against a variety of tumors in murine 
models. It is curative against intravenously implanted P 388 leukemia and intravenously 
as well as subcutaneously implanted Lewis lung carcinoma, and has a high degree 
of activity against subcutaneously implanted solid tumors including, chomorefractory 
tumors such as mouse colon adenocarcinomas 38 and 51, mammary 16/c tumor 
and human colon carcinoma xenograft HT-29 (40,54). Topotecan has been compared 
with camptothecin and 9-amino-camptothecin (a camptothecin analogue with an 
amino group at the 9 position, insoluble in aqueous solutions> in intravenously or 
intraperitoneally implanted L 1210 leukemia, intraperitoneally implanted P388leukemia, 
a camptothecin resistant P388 subline, s.c Lewis lung carcinoma, s.c B16 melanoma 
and s.c colon carcinoma 51. In addition, topotecan and 9-amino- topotecan were 
compared in nude mice bearing subcutaneously implanted xenografts of human colon 
tumors HT-29 and SW-48. Topotecan had superior activity in Lewis lung carcinoma 
and B16 melanoma and was the only compound of the three that induced regressions 
in the lung tumor model. Topotecan and 9-amino-camptothecin had similar activity 
in the leukemias and were more effective than camptothecin; all three were ineffective 
against in the P388 camptothecin resistant subline. Comparable extensive tumor 
growth delays were produced by all three agents in the murine colon tumor 51 model. 
Topotecan, like 9-amino-camptothecin, produced regressions and tumor growth delays 
in the human colon tumor xenografts; however, the duration of regression was superior 
for 9-amino-camptothecin (55). The preclinical toxicology studies of topotecan revealed 
thattoxicity was dose related, reversible and limited to fast proliferating tissues such 
as bone marrow and gastro-intestinal epithelium. 
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From the murine models no single optimal dosing schedule could be defined for phase 
I clinical testing. Activity is retained when topotecan is administered intravenously, 
intraperitoneally, subcutaneously or orally. 
Recent data from preclinical studies suggest that daily administration for a prolonged 
time is associated with an increased antitumor effect (36,56,57). A study comparing 
different dosing schedules of topotecan in in vitro tumor colony formation from freshly 
ex planted human tumors showed that the activity of topotecan was more effective 
in the continuous exposure than in the short (1-hour) exposure experiment (57). 
Phase I studies: 
Table 2 summarizes the single agent phase I studies of topotecan (43,44,47-49,51-
53,58-63). In these studies many different schedules have been tested; a single 30 
minute infusion every 3 weeks, a 30 minute daily infusion during 5 days every 3 
weeks, a 24 hour infusion weekly or every 3 weeks, and a 72 or 120 hour infusion 
repeated every week or at 3 weeks intervals. In addition, recently topotecan was 
administered as a continuous infusion during 21 days. In all studies except one involving 
leukemic patients the dose limiting toxicity was neutropenia either alone or in conjuncti-
on with thrombocytopenia. The neutropenia usually occurred between day 8 and 
10, was generally brief and rarely associated with fever or treatment delays. At 
subsequent courses there was no evidence of cumulative toxicity. The maximum 
tolerated dose (MTD) was very schedule dependent. The highest amount of topotecan 
could be delivered as a short 30 minute infusion every 3 weeks (22.5 mg/m'). 
Intermittent or prolonged infusion led to a relative increase in toxicity except the 
study using a 21-day continuous infusion. In this study the dose limiting toxicity 
occurred at a dose level of 0.7 mg/m'/day. The total course dose in this study is 
much higher compared to the other studies using schedules with prolonged infusion 
times. 
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TABLE 2: PHASE I STUDIES OF TOPOTECAN 
Schedule Ref. MTO· mg/m2/d Total course dose Dose limiting toxicity (OL T) 
(phase II) mg/m2 
30 min. infusion every 3 weeks 44,45 22.5 22.5 Neutropenia ! 
30 min. infusion daily x 5 every 43 1.5·2 7.5 - 10 Neutropenia 
3 weeks 
30 min. infusion daily x 5 every 47 1.5 7.5 Neutropenia 
3 weeks 
30 min. infusion daily x 5 every 49 1.5 (1.5) 7.5 Neutropenia 
3 weeks 
24 hr. infusion every 3 weeks ~~ 48,52 5.5 5.5 Neutropenia/thrombocytopenia 
24 hr. infusion every 3 weeks 53 PT4 PT4 Neutropenia/thrombocytopenia 
UT 5 UT 5 
24 hr. infusion every 3 weeks 58 8.4 8.4 Neutropenia/thrombocytopenia 
24 hr. infusion weekly 46 1.75 (1.5) 1.5 Neutropenia 
120 hr. infusion every 3 weeks 51,59 0.68 3.4 Neutropenia 
72 hr. infusion every 3 weeks 59 1.6 4.8 Neutropenia 
72 hr. infusion every 3 weeks·· 60 1.0 3.0 Neutropenia 
weekly 72 hr. infusion 61 2.0 (2.0)···· 6.0 Myelotoxicity 
120 hr. infusion every 3 weeks··· 62 2.0 10.0 Mucositis 
3 weeks continuous infusion 63 0.7 14.7 Not reached 
--_. --_.-
.. Maximum tolerated dose (recommended phase II dose), ... Pediatric study, ...... Leukemic patients, ....... mg/m2/72 hr, PT: pretreated, UT: untreated 
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There were only minimal differences in the magnitude of neutropenia in heavily versus 
minimally pretreated patients. Only one study (46) recommended different doses 
for untreated and pretreated patients in phase II studies. Mild anemia occurs but 
is not a clinically significant problem. Non·hematological toxic effects include nausea 
(12%). vomiting (10%), alopecia (11 %), diarrhea (11 %). fever (4%), fatigue (3%). 
and skin rash (2%). Rarely, mild elevation in liver function tests occurs. Hemorrhagic 
cystitis, one of the dose limiting toxicities of the parent drug camptothecin, was 
not reported. 
As neutropenia is the dose limiting toxicity, the feasibility of further dose escalating 
in combination with hematopoietic growth factors has been evaluated in two studies, 
with conflicting results. Murphy et al. (64) started granulocyte colonY'stimulating 
factor (G·CSF) 5 Jig/kg subcutaneously once daily from day 6 until full recovery, 
in a pretreated group of patients who were treated with topotecan 1.5 mg/m'/d for 
5 consecutive days as a 30 minute infusion. There was no effect on the day of nadir 
of the neutrophils, but the median duration of the neutropenia was only 2 days (range 
0·5). However, the dose of topotecan could not be escalated as thrombocytopenia 
emerged as the dose limiting factor. In contrast Rowinsky et al. (65) showed that 
the same approach resulted in a higher neutrophil nadir without coinciding worsening 
of the platelet nadir, allowing further dose escalations. An interesting observation 
in the latter study was that concurrent administration of G·CSF with topotecan resulted 
in a more severe neutropenia and thrombocytopenia. This might reflect the G-CSF 
induced increase in the fraction of precursors transversing the S-phase concurrent 
with a S-phase selective cytotoxic agent. 
In a recent study the effect of administration of prechemotherapy hematopoietic growth 
factors was evaluated (66). Hematopoietic growth factors can reduce the duration 
of neutropenia following chemotherapy but have no effect on the depth of the neutrophil 
nadir. All patients received topotecan at a dose of 1.5 mg/m' daily for 5 days followed 
by granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 Jlg/m' sub-
17 
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cutaneously once daily for 7 days. Patients were randomized between no or pre· 
chemotherapy GM·CSF, at a dose of 250 flg/m 2 twice daily subcutaneously for 5 
days before the topotecan infusions. A substantial decrease in the incidence of grade 
4 neutropenia was observed, 27% in the prechemotherapy GM·CSF group versus 
77% in the group not receiving prechemotherapy GM·CSF. Whether prechemotherapy 
hematopoietic growth factor administration allows further dose escalation with 
topotecan needs to be studied. 
During phase I trials responses with topotecan have been observed in non·small cell 
lung cancer (1 complete response (CR), 4 partial responses (PR), epithelial ovarian 
cancer (1 PRj, small·ceiliung cancer (1 PRj, oesophageal cancer (1 PRj, colorectal 
cancer (1 PR), pancreatic cancer (1 PRj and acute leukemia (3 CR and 2 PRj. In addition, 
minor responses have been observed in renal cell cancer, squamous cell carcinoma 
of the skin, non·small lung cancer and ovarian carcinomas. 
The most convincing evidence of antitumor activity occurred with the daily x5 schedule 
and the 21·days continuous infusion schedule. These phase I observations in 
combination with the observation, that in preclinical models intermittent and prolonged 
infusion times are more effective, have prompted initiation of phase II trials utilizing 
topotecan in a dosing schedule of 1.5 mg/m2/d administered as 30 minute infusions 
for 5 consecutive days being repeated every 3 weeks. In addition phase II studies 
with the 21·days continuous infusion schedule are planned. 
Phase /I studies: 
Phase II trials are ongoing with the daily x5 schedule in many different tumor types. 
The preliminary results of four published studies are summarized in table 3 (67·70). 
From these studies it can be concluded that with this dosing schedule topotecan 
is not active in renal cell carcinoma and hormone refractory prostate carcinoma. 
Topotecan has definite activity in ovarian canCer refractory to cisplatin and/or 
carboplatin therapy and exerts some antitumor activity in colorectal cancer. Further 
studies have to be awaited. 
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TABLE 3: PHASE II STUDIES WITH TOPOTECAN 
Tumor type Schedule Prior No. patients Response Toxicity 
(Reference) chemotherapy 
Prostate (67) 1.5 mg/m2 d x 5 PT 28 2 x PR Neutropenia ;,,; grade 3: 27/84 
every 3 weeks 8 x SO cycles (32.1 %) 
Oose reduction 9/28 pts 
(32.1 %) 
Treatment delay 22/84 cycles 
(26.2%) 
Renal cell (68) 1.5 mg/m2/d x 5 UT 15 2 x MR Neutropenia ;,,; grade 3: 12/15 
every 4 weeks 7 x SO (80%) 
Epithelial ovary (69) 1.5 mg/m2/d x 5 PT 28 4 x PR Treatment delay 57% 
every 3 weeks 7 x SO 
Colorectal (70) 1.5 mg/m2/d x 5 UT 16 1 x PR Leucopenia (97%). being grade 
every 3 weeks 3·4 in 50%, thrombocytopenia 
, 
_ ... __ ..... 
(47%) 
-_. -_ .. 
-- - -
PT : pretreated, UT : untreated, PR : partial response, SO : stable disease, MR : minor response 
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IRINOTECAN (CPT-11) 
Clinical pharmacology: 
Like topotecan, CPT-ll (7-ethyl-l0 [4-(piperidino)-1-piperidinoJ carboxyloxy-campto-
thecin) is a semisynthetic analogue of camptothecin with improved watersolubility 
(figure 3). 
In vivo, CPT-ll is converted to its active metabolite 7-ethyl-l O-hydroxy-camptothecin 
(SN-38), which in vitro has a 1 OO-fold or more antitumor activity than CPT-ll (figure 
3) (71,72). Incubating CPT-ll with mouse serum or with homogenates of liver or 
intestinal mucosa before adding tumor cells results in an enhanced growth inhibitory 
activity which is coincided with the formation of SN-38 (73). Thus CPT-ll acts as 
a prodrug, mainly expressing antitumor activity after enzymatic conversion to its 
active form. It is speculated that the enzyme responsible for converting CPT-ll to 
SN-38 is carboxylesterase (74). A study comparing the metabolism of CPT -11 resistant 
non-small cell lung carcinoma cells (PC-7/CPT) to the CPT -11 sensitive parent cells 
(PC-7IS) showed that there was no difference in the intracellular accumulation of 
CPT-11, but the intracellular level of SN-38 was decreased in the CPT -11 resistant 
cells. The enzymatic carboxylesterase activity of these cells was decreased to one 
third compared as to the activity in the parent cells also suggesting that carboxy-
lesterase is responsible for the conversion of CPT-11 in SN-38 (75). 
In mice the plasma CPT -11 concentration decreases biexponentially after intravenous 
administration of CPT-11, with a biological half life 0.8 to 1.1 hour. 
The area under the plasma concentration-time curve shows dose dependency. The 
peak plasma concentrations of SN-38 are approximately 100-fold lower than the 
peak plasma concentrations of CPT -11 . The SN-38 concentration decreases forthe 
first 30 minutes after administration and is then maintained stable for a few hours 
followed by the log-linear terminal phase with a half life of approximately 2 hours. 
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This elimination is independent of the dose. Maintenance of the plasma concentration 
of SN-38 is presumed to be caused by two mechanisms. One is that the concentration 
is the sum of the linear formation of SN-38 from CPT-11 in the blood and the liver, 
the other is that SN-38 elimination from the plasma is saturated or inhibited by 
coexisting CPT-11 (73,76). 
Although peak plasma SN-38 concentrations achieved after direct intravenous 
administration of SN-38 to mice are higher compared to peak plasma SN-38 
concentration after CPT-11 administration, the effective cytotoxic plasma concentration 
were sustained for a longer period after conversion from the CPT-11. The antitumor 
activity of CPT-11 and SN-38 are time dependent rather than dose dependent, except 
at extremely high concentrations (35,77). 
The clinical pharmacology studies of CPT-11 have only mainly been reported in a 
preliminary form. Table 4 summarizes the pharmacokinetic parameters noted CPT-11 
and SN-38 (78-85). Interpretating these pharmacokinetic parameters is difficult, not 
only caused by the diversity of schedules and/or infusion times. First, like topotecan 
and camptothecin, both CPT-11 and SN-38 undergo a pH-dependent hydrolysis from 
active lactone forms to hydroxy acid forms. In the earlier trials (82,83) the available 
HPLC assays only allowed measuring of the total concentration of CPT -11 and SN-38. 
In humans a rapid hydrolysis of both CPT-11 and SN-38 is observed, with equilibria 
established within 30 to 60 minutes after administration. At equilibrium 33-55% 
of the total CPT-11 and SN-38 are present as lactones, with stable proportions 
thereafter (80). Second, in all these studies there was a interindividual variability 
in the pharmacokinetics of CPT-11, implicating large interindividual differences in 
the metabolism and/or elimination. Third, the available data seem conflicting. In the 
earlier studies the pharmacokinetics of CPT-11 appeared to be non-linear (82,83), 
whereas more recent studies suggest a linear relation (78,79,80,84,85). 
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TABLE 4: PHARMACOKINETICS OF CPT-11 
Schedule Ref. t% (h) Peak plasma Peak plasma AUC AUC Clearance VOss 
(SN-38) concentration concentration CPT-11 SN-38 II/h/m2) 111m2) 
CPT-" SN-38 lpg/ml) lpg.h/ml) lpg.h/ml) 
lpg/mll 
90 min. infusion 100 78 7.9 1.37 30.35 2.79 0.21 14.7 -
mg/m2 weekly x 4 79 (15.8) 
90 min. infusion 80 3 - - - - 18.6 33 
every 3 weeks 
90 min. infusion 100 81 - 1.35 26.20 6.41 0.23 - -
mg/m2 weekly x 4 
90 min. infusion 100 82 1.5 1.42 18.0 6.37 0.2 17.6 -
mg/m2 weekly (3.0) 
120 hr. continuous 83 37.7 0.15 10.5 20.5 0.96 55.0 -
infusion (30 mg/m2 (23.9) 
per day) 
30 min. infusion 84 17 - - - - 15.0 150 
every 3 weeks 85 
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Peak plasma concentrations of CPT -11 occur directly after the infusion whereas peak 
plasma concentrations of SN~38 are observed at variable times. Like in murine models, 
the peak SN-38 concentrations and the AUC do not correlate with CPT-11 dose. 
There are no data in humans, about elimination of CPT-11. In rats, within 24-hours 
33-58% of unchanged CPT-11 given intravenously is excreted in the bile and the 
urine. The metabolite SN-38 is mainly excreted into the bile (73,76). 
Until now, there is no clear correlation between toxic effects and pharmacokinetic 
parameters. If more pharmacokinetic data become available pharmacodynamic 
parameters of both CPT-11 and its active metabolite SN-38 might become better 
defined. 
Preclinical studies: 
CPT-11 demonstrated significant antitumor activity against a broad spectrum of experi-
mental tumors. Among the most sensitive tumors were S180, Meth-A fibrosarcoma, 
Lewis lung carcinoma, Ehrlich carcinoma, MH 134 hepatoma, mammary carcinoma 
of C3H/HeN mice, L 121 0 and P388 leukemia. Probable cures of these tumors were 
observed frequently. Almost all mice bearing S180 and Lewis lung carcinomas were 
cured by CPT-11 (86). CPT-11 was also highly effective against early and advanced 
stage pancreatic ductal adenocarcinoma 03, with 5/5 complete regressions and 3/5 
longterm survivors (87,88). Activity was further observed in B16 melanoma and 
colon carcinomas 38 and 51. Comparing the activity of CPT-11 against L 1210 leukemia 
to camptothecin and other analogues revealed that CPT-11 was the most effective, 
giving the highest maximum increased life span (lLS) over a broad dose range. Moreover 
comparing the antitumor activity of CPT-11 against intra peritoneally implanted L 1210 
leukemia to adriamycin showed that CPT-11 was superior to adriamycin in maximum 
ILS (300% versus 129%), the number of cured mice (5/6 versus 116) and therapeutic 
ratio (86). Administration of CPT -11, intravenously or orally was significantly effective 
against human tumor xenografts transplanted in nude mice. CPT-11 showed antitumor 
activity against coloncarcinoma CoA, mammary carcinoma MX-1, gastric adeno-
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carcinoma ST-15 and SC-16, and squamous cell lung carcinoma QG-56 (89). CPT-11 
showed activity against human tumor cell lines, resistant to vincristine, doxorubicin, 
colchicine and vinblastine which is related to the total different mechanism of action 
of CPT-11 as compared to these drugs (90). 
Like topotecan no single optimal dosing schedule could be defined for phase I testing, 
but in a study in human cell lines it is suggested that more prolonged exposure to 
CPT-11 has a better cytotoxic effect (91). 
Phase I studies: 
The first phase I study was conducted in 1987 in Japan (92). Subsequent studies 
were performed in Japan, France and the United States. Table 5 summarizes the 
recently published data of phase I studies of CPT-11 (78-80,82,83,93-97). In these 
studies a wide range of schedules have been used; a single 30 minute infusion weekly 
or every 3 weeks, a 90 minute infusion weekly or every 3 weeks, a 30 minute infusion 
daily for 3 days every 3 weeks, and a 5 days continuous infusion every 3 weeks. 
The dose limiting toxicities in all these studies were mainly neutropenia and diarrhea. 
The neutropenia is, like for topotecan, dose related, generally brief and non-cumulative. 
Infrequent mild to moderate thrombocytopenia or anemia are also reported. Two 
types of diarrhea are observed. The first is an early onset type which begins during 
or immediately after the infusion of CPT -11. This diarrhea is often coincided by abdo-
minal cramping and facial flushing, suggesting that it is mediated by vaso-active 
substances. In vitro it has been demonstrated that CPT-11 inhibits acetylcholine esterase 
activity (74). These acute gastrointestinal side effects are fairly well controlled by 
the use of standard dose of anticholinergic drugs such as scopolamine butyl bromide 
or atropine sulphate. 
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TABLE 5: PHASE I STUDIES OF CPT-11 
Schedule Ref. MTD mg/m2/d n Dose limiting toxicity Other adverse events 
5 days continuous 83 30 (30) Diarrhea Nausea, vomiting, leucopenia, anemia, 
infusion hepatic dysfunction 
30 min. weekly 93 145(115) Diarrhea, leucopenia Vomiting, fatigue, alopecia, 
infusion stomatitis 
90 min. weekly 82 100 (100) Neutropenia, diarrhea Nausea, vomiting, thrombocytopenia, 
infusion alopecia, hepatic and renal dysfunction, 
pneumonitis 
90 min. weekly 78 > 100 - Neutropenia, diarrhea, nausea, vomiting, 
infusion 79 anorexia, alopecia 
30 min. infusion x 94 115 Neutropenia Diarrhea, nausea, vomiting, alopecia, fatigue 
3 every 3 weeks 95 
30 min. infusion 96 400 - Leucopenia, neutropenia, anemia, 
every 3 weeks 97 thrombocytopenia, vomiting, diarrhea, 
alopecia, malaise, hyperperistalsis 
90 min. infusion 80 240 (240) Neutropenia, vomi- Thrombocytopenia, alopecia, anorexia, 
every 3 weeks ting, nausea malaise, abdominal cramps, flushing, diarrhea 
30 min. infusion 98 ",600 - Neutropenia, anemia, thrombocytopenia, 
every 3 weeks nausea, vomiting, diarrhea, alopecia, 
transient elevation transaminases 
n Recommended phase II dose 
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With prophylactic use of 5HT-3 antagonist-ondansetron in combination with the H 1-
histamine antagonist diphenhydramine, the acute adverse gastrointestinal toxicities 
could be prevented. Furthermore it permitted further dose escalation of CPT-11 (80). 
The second type of diarrhea is a delayed type occurring after several days. It can 
present as a cholera-like secretory diarrhea, leading to severe dehydration, requiring 
intravenous rehydration. Milder forms of this delayed type of diarrhea respond to 
the standard anti-diarrheal drugs such as loperamide. Other toxicities include malaise, 
alopecia, rash, mild elevations of liver function tests, nausea and vomiting. There 
has been no evidence of hemorrhagic cystitis. 
During the phase I studies responses with CPT-11 have been observed in different 
tumor types, including non-small cell lung cancer (82), colon carcinoma (96,97,98), 
cervix carcinoma (93,98), mesothelioma (94,95) and breast carcinoma (94,95). Minor 
responses have been noted in oesophageal carcinoma (93), renal cell carcinoma (93), 
ovarian carcinoma (93), hepatoma (78,79), colon carcinoma (78,79,94-97), pancreatic 
carcinoma (94,95) and head and neck cancer (96,97). 
In Japan, the recommended scheme for phase II studies is a weekly CPT-11 infusion 
of 100 mg/m2 • This is based on the apparent augmentation of the dose intensity 
with this weekly scheme compared to a single infusion every four weeks, which 
resulted in phase I studies to a dose intensity of 50 mg/m2 per week. Instead, in 
Europe phase II studies are started with a single infusion of 350 mg/m2 of CPT-11 
repeated every three weeks, because in phase I studies performed in Europe this 
dosing schedule resulted in an increased dose intensity. 
Phase /I studies: 
Phase II studies with CPT-11 have been performed in Japan. In the USA and in Europe 
many phase II studies are ongoing. Table 6 and 7 summarize the results of the phase 
II studies of CPT-11 in solid tumors and in hematological malignancies. These early 
results suggest that CPT-11 is active against a broad spectrum of human tumors. 
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TABLE 6: PHASE II STUDIES OF CPT-11 IN SOLID TUMORS 
Tumor type Ref. Prior therapy' Schedule mg/m2 No. of evaluable Number of responses Response 
patients CR PR rate (%) 
Lung, non-small cell 99 UT 90 min. infusion, 72 0 23 32 
100 mg/m2 weekly 
lung, small cell 100 PT/UT 90 min. infusion, 27/8 2/0 7/4 33/50 
100 mg/m2 weekly 
Gastric 101 PT/UT 100 mg/m2 weekly 45/15 0 9/5 23 
or 150 mg/m2 
every two weeks 
Pancreas 102 PT/UT 100 mg/m2 weekly 35 0 4 11,4 
or 150 mg/m2 
every two weeks 
Colorectal 103 PT/UT 90 min. infusion 51/12 0 13/4 27 
100 mg/m2 weekly 
or 150 mg/m2 
every two weeks 
Epithelial ovary 104 PT 100 mg/m2 weekly 14 1 2 21 
or 150 mg/m2 
every two weeks 
or 200 mg/m2 
every 3-4 weeks 
Cervix 105 UT 100 mg/m2 weekly 55 5 8 24 
or 150 mg/m2 
every two weeks 
- -- ------
UT : untreated, PT : pretreated 
Tumor type Ref. 
Non Hodgkin 106 
lymphoma 
Non Hodgkin 107 
lymphoma 
Hodgkin 107 
lymphoma 
Acute 106 
leukemia 
.... 
UT : untreated 
PT : pretreated 
TABLE 7: PHASE II STUDIES OF CPT IN HAEMATOlOGICAl MALIGNANCIES 
Prior therapy . Schedule mg/m2 No. of evaluable Number of response Response 
patients CR PR rate (%) 
PT 200 mg/m2 every 3-4 6 0 0 0 
weeks 
40 mg/m2 daily x 5 16 2 3 31 
every 3-4 weeks 
40 mg/m2 daily x 3, 8 0 1 33 
weekly 
20 mg/m2 twice daily x 2 8 0 0 
7 every 3-4 weeks 
PT 40 mg/m2 daily x 3, 47 8 15 49 
weekly ! 
PT 40 mg/m2 daily x 3, 4 0 0 0 
! weekly 
PT 200 mg/m2 every 3-4 4 0 0 0 
weeks 
40 mg/m2 daily x 5 9 0 0 0 
every 3-4 weeks 
40 mg/m2 daily x 3, 1 0 0 0 
weekly 
20 mg/m2 twice daily x 12 1 2 25 
7 every 3-4 weeks 
Chapter 2 
For the studies in solid tumors CPT-11 was mostly administered once weekly or once 
every two weeks. Activity was seen both in untreated patients as well as patients 
previously treated with chemotherapy and/or radiotherapy. 
In a study with patients with untreated non-small cell lung cancer 23 partial responses 
were reported among the 72 evaluable patients, with a median duration of response 
of 15 weeks (99). CPT-11 seems to be more active than other currently available 
single agents. CPT-11 also showed clear activity against gastric carcinoma (23%), 
colorectal carcinoma (27%), small cell lung cancer (33%-50%), cervical carcinoma 
(24%) and epithelial ovarian carcinoma (21 %), but the overall median duration of 
response was short, varying from 50 to 68 days. The response rate of 11.4 % in 
pancreatic carcinoma with this dosing schedule seems to be of no clinical relevance 
(102). 
In hematological malignancies activity of CPT-11 was mainly reported in schedules 
using daily infusions for a prolonged time (106,107). It would be of interest to study 
the feasibility of these intensive dosing schedules in solid tumors. 
Side effects in phase II studies are similar compared to the toxicities noted in phase 
I studies, with the exception of pulmonary toxicity that was more frequent in phase 
II studies. This serious complication seems to be exclusive to patients with lung cancer. 
It was only noticed once in a phase I study (82). In a study with previously untreated 
non-small cell lung carcinomas this complication was observed in 6 patients (8%). 
Dyspnea on exertion developed in five patients and fever in four. Five of them showed 
a diffuse reticular nodular pattern on a chest X-ray and in one patient abnormalities 
highly suggestive of interstitial infiltrates were seen on a CT scan. In three patients 
eosinophilia was found concomitant with pulmonary toxicity. The interval from beginning 
of the administration of CPT-11 to the onset of the pulmonary symptoms ranged 
from 42 to 175 days, with a median of 61 days. A median total dose of CPT-11 
in these patients was 750 mg/m2, with a range of 400 to 1000 mg/m2 • In one patient 
the toxicity resolved spontaneously within one week. 
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The other patients were treated with corticosteroids, which seems to be beneficial. 
One patient died of respiratory failure (99). In another study involving relapsed or 
refractory small cell lung cancer the complication was seen in two patients (13%). 
Transbronchial biopsy showed interstitial edema associated with fibroblastic prolife· 
ration, lymphoid cell infiltration and with the formation of hyaline-like membranes 
in several air spaces caused by a fibrinous exsudate. One patient responded to 
corticosteroids, in the other the pneumonitis caused progressive respiratory failure 
and death (108). 
COMBINATION THERAPY 
In view of the single agent activity of topoisomerase I inhibitors, recently studies 
are started focusing on combination strategies. In vitro and/or in vivo the topoisomerase 
I inhibitors are combined with other cytostatic agents, radiotherapy and hyperthermia. 
The combination of topoisomerase I inhibitors with cisplatin has been reported to 
be additive (55,109-111). This combination might be very promising as the drugs 
have non-overlapping toxicities, different mechanisms of action, and topoisomerase 
I inhibitors potentially can interfere with the repair from cisplatin induced DNA damage, 
a major mechanism of cisplatin resistance. In a phase I study, escalating doses of 
CPT-11 were administered as a 90 minute infusion on day 1, 8, and 15 every four 
weeks with a fixed dose of cisplatin of 80 mg/m2 on day 1 (112). At the dose level 
of 70 mg/m2 of CPT-11, diarrhea and neutropenia were the dose limiting toxicities. 
There were 14 partial responses among the 26 evaluable patients (a response rate 
of 54%). Recommended dose for phase II studies is CPT-11 60 mg/m2 on day 1,8,15 
and cisplatin 80 mg/m2 on day 1, cycles to be repeated every four weeks. 
Based on the assumption of the existence of a dose·response relationship a subsequent 
study was performed where an attempt was made to further escalate the dose of 
CPT ·11 by adding G-CSF. CPT -11 was given on day 1, 8, and 1 5, with a starting 
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dose of 60 mg/m2, repeated every four weeks, again combined with cisplatin at a 
dose of SO mg/m2 on day 1, plus G-CSF at a dose of 2pg/kg administered once daily 
from day 4-21 except on the days of CPT-11 was given. The use of G-CSF allowed 
safe administration of SO mg/m2 of CPT-11 combined with SO mg/m2 of cisplatin, 
a 33.3% dose intensification, without the occurrence of dose limiting diarrhea or 
leucopenia. Eight partial responses out of the 19 evaluable patients were noted 
(response rate of 42%). In these two studies there was a clear linear relationship 
between the Cmax of SN-3S and the severity of diarrhea (113). 
Topotecan has also been used in conjunction with cisplatin. In one study the dose 
limiting neutropenia occurred at the dose level of 75 mg/m 2 of cisplatin given on 
day 1 and topotecan at a dose of 1.0 mg/m2/day for 5 consecutive days. It was conclu-
ded that the combination of topotecan with cisplatin is more toxic than either drug 
given alone (114). In the other study patient accrual only recently started althe dose 
level of 1.0 mg/m'/day of topotecan (115). 
While the concomitant combination of topoisomerase I and II inhibitors appears antago-
nistic (111,117, 11S), the sequentially combination of the two types of drugs appears 
additive or synergistic (55, 116-11S). The synergism might be related to the upregulation 
of cellular topoisomerase II levels which have found to increase 24-4S hours after 
exposure to topoisomerase I inhibitors (119). Based on these data two phase I studies 
have been performed with the combination of topoisomerase I and II inhibitors. The 
first was a Japanese study including patients with advanced lung cancer and these 
patients were treated with escalating doses of CPT-11, administered on day 1, S, 
and 15 in combination with fixed doses of SO mg/m2 etoposide on day 1, 2, and 
3 plus G-CSF 2 pg/kg given subcutaneously once daily from day 4-21, except on 
the days of CPT-11 administration. This treatment was repeated every four weeks 
(120). The dose limiting toxicity was reached at a dose level of SO mg/m2 of CPT-11 
and consisted of diarrhea and neutropenia. Seven partial responses (37%) and one 
complete response (5%) were noted among the 19 assessable patients. 
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The overall response was 58 % for the small cell lUng cancer patients and 15 % for 
the non-small cell lung cancer patients. The recommended CPT-ll dose for phase 
II studies is 70 mg/m2 • Escalating doses of topotecan given as a 3 days continuous 
infusion, with a starting dose of 0.17 mg/m2/day, was tested in combination with 
etoposide with a fixed dose of 100 mg/m2 , given as a 2 hours infusion, on day 7, 
8 and 9. The hematological toxicities were more severe than expected, especially 
in pretreated patients. These toxicities might reflect a synergistic effect of the 
combination, but this hypothesis has to be studied in the future with previously 
untreated patients with detailed pharmacokinetic monitoring (11 9). 
From in vitro studies synergistic activity has also been observed when CPT -11 was 
combined with cytosine arabinoside or mitomycin C. Additive effects were observed 
for its combination with amsacrine, bleomycin, vincristine and 5-fluorouracil (111). 
These results might be used for the design of future in clinical trials. 
The primary cytotoxic effect of ionizing radiation is DNA damage. Normally, most 
forms of DNA damage can be reversed by means of a number of repair pathways. 
In a variety of preclinical models camptothecin, topotecan and CPT-ll have been 
shown to enhance the lethality of ionizing radiation (121-1 24). It is suggested that 
this enhancement of cytotoxicty is caused by the inhibition of the DNA repair by 
the topoisomerase I inhibitors. 
Hyperthermia is an other local treatment that has been explored in combination with 
topoisomerase I inhibitors. Hyperthermic treatment of the tumor bed enhances the 
cytotoxicity of topoisomerase I inhibitors in FSall C murine fibrosarcoma cells (125). 
Both radiotherapy as well as hyperthermia in combination with the camptothecin 
analogues have not been applied in the clinical setting. 
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MECHANISMS OF RESISTANCE TO TOPOISOMERASE I INHIBITORS 
Resistance to the cytotoxic effects of topoisomerase I inhibitors has been induced 
by selecting cells for their ability to survive continuous exposure of increasing 
concentrations of drug. These drug resistant cell lines provide powerful tools for 
understanding the mechanisms how cellular sensitivity to these agents is controlled, 
their target sites and the mechanisms of acquirement of drug resistance (126,127). 
Different mechanisms appear to be involved in drug resistance. First, reduced levels 
of topoisomerase I have found to occur frequently in tumor cells (128). Mutations 
that alter in the affinity of the drugs to topoisomerase I represent another recognized 
mechanism of resistance. A human cancer cell line selected under continuous exposure 
to camptothecin was shown to contain topoisomerase I having a single amino acid 
change which related camptothecin resistance (129). In a CPT-11 resistant human 
lung cancer cell line (PC-7/CPT) resistance is caused by pleiotropic changes; decreased 
levels of topoisomerase I, low affinity of the drug to topoisomerase I and low affinity 
of carboxylesterase which catalyses CPT-11 to its active metabolite SN-38 (72). 
Lengthening of the cell cycle may also be a mechanism of resistance in certain tumors 
that contain a large fraction of non-S-phase cells (130). Overexpression of the MDR-1 
gene is a major general cause of drug resistance. The topoisomerase I inhibitors 
camptothecin and CPT-11 are unaffected with increase in P-170 membrane glycoprotein 
expression (90). In contrast, topotecan, a positively charged camptothecin analogue, 
shows a decreased accumulation and cytotoxicity in cells overexpressing MDR-1 
(131,132). This effect of P-170 glycoprotein pump mechanism on the uptake and 
cytotoxicity of topotecan is small compared to the effect in the uptake and cytotoxicity 
of doxorubicin or etoposide in the same cell lines. Whether this mechanism of resistance 
to topotecan is of any clinical relevance needs to be investigated. 
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CONCLUSIONS 
Topoisomerase I inhibitors have a novel mechanism of action and they seem to have 
activity against a broad spectrum of tumors, including to tumors which are resistant 
to the currently available chemotherapeutic drugs. Further preclinical and clinical 
studies are in progress to define the role of topoisomerase I inhibitors in cancer therapy. 
Many questions remain unanswered. For example, the optimal dosing schedule is 
unknown. From preclinical models it seems that prolonged exposure is superior. In 
a recently published clinical study it has been reported that a continuous infusion 
of topotecan for 21-days has an excellent tolerance with evident antitumor activity. 
So far most phase II studies and topotecan have been performed with dosing schedules 
using short infusion times for 5 days. 
As topoisomerase I inhibitors are unlikely to be curative as a single agent, the 
combination of these drugs with other chemotherapeutic agents, radiotherapy and 
biological response modifiers need to be studied. 
In addition, testing of new camptothecin analogues and oral formulations are important 
issues for evaluating the role of topoisomerase I inhibitors in cancer therapy. 
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SUMMARY 
Purpose: This phase II study with the topoisomerase I inhibitor topotecan was performed 
to determine its clinical activity and toxicity in patients with metastatic or locally 
irresectable colorectal cancer. 
Patients and methods: Topotecan 1.5 mg/m'/day was administered intravenously 
by 30 minute infusion for 5 days repeated every 3 weeks. Fifty-nine patients entered 
the study. Two were considered to be ineligible, 57 patients were evaluable for response 
and toxicity. 
Results: A partial response was obtained in 4 of 57 evaluable patients (7%). The 
median duration of the response was 11 months (range 9.3 to 12.2). This topotecan 
regimen was very well tolerated. A total of 290 courses were given, with a median 
of 4 courses per patient (range, 1 to 18). The major toxicity was leuco- and neutropenia 
(91 %), being grade 3-4 in 48% and 79% of courses respectively, but with only 2 
infectious complications. Other side effects were alopecia (77%). being grade 1 in 
46%, nausea (35%), vomiting (10%). and maculo-papular rash (6%). 
Conclusion: Topotecan administered as a daily times five regimen only has minor 
activity as a single agent therapy in colorectal cancer. 
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INTRODUCTION 
5-Fluorouracil (5-FU) is still the mainstay of systemic treatment for patients with 
metastatic colorectal cancer, with reported response rates averaging 5-20 %, usually 
of short duration. Biomodulation of 5-FU induces higher response rates, but the impact 
on survival has been minimal (1,2). Thus, new active antitumor agents are needed 
to improve the prognosis of these patients. 
T opotecan, (S)-9-dimethylaminomethyl-1 O-hydroxycamptothecinhydrochloride, is 
a semisynthetic watersoluble analogue of the parent drug camptothecin. Topotecan 
is a specific inhibitor of the enzyme topoisomerase I (3,4). Its detailed mechanism 
of action has extensively been reported elsewhere (5). 
Topotecan was shown to have antitumor activity against a variety of tumors in preclini-
cal testing such as P 388 leukemia, Lewis lung carcinoma, mouse colon carcinoma 
38 and 51 and human colon carcinoma xenograft HT-29. In all phase I studies reversible 
non-cumulative neutropenia either alone or in conjunction with mild thrombocytopenia 
was the dose-limiting toxicity (5). The daily x 5 schedule was selected for phase 
II studies. We performed a phase II study in metastatic colorectal cancer. 
PATIENTS AND METHODS 
Patients 
Patients with metastatic or irresectable locally advanced colorectal cancer were 
included. Eligibility further required; (1) measurable disease; (2) age,;; 75 years; 
(3) WHO performance status';; 2; (4) adequate bone marrow function (white blood 
cells (WBC) ;,: 3.5 x 10'/1, granulocytes;,: 1.5 x 10'11 and platelets;,: 100 x 10'11); 
(5) serum creatinine';; 140 pmolJl; (6) serum bilirubin,;; 25 pmol/l, serum SGOT JPT 
,;; 2x the upper limit of normal, in instances of liver metastasis,;; 5x the upper limit; 
(7) no prior chemotherapy for advanced disease (an interval of at least twelve months 
was required since prior adjuvant chemotherapy); (8) informed consent. 
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Treatment schedule 
Topotecan 1.5 mg/m'/day was administered as a 30 minute infusion for 5 consecutive 
days every 3 weeks. Topotecan was supplied in vials as a light yellow, lyophilized 
cake. Each lyophilized vial contained 5 mg of the free base. The lyophilized formulation 
was reconstituted with 2 ml of sterile water for injection prior to dilution with 5 % 
dextrose injection. In instances of bone marrow suppression retreatment was postponed 
until full hematological recovery. If a delay in the treatment cycle was more than 
2 weeks, the daily infusion dose was decreased by 0.25 mg/m'/day. The infusion 
dose was reduced by 0.5 mg/m'/day if granulocytes were';; 0.5 x 109/1 and/or platelets 
,;; 50 x 1 09 11 lasting for more than 14 days; or if grade 3-4 non-hematological toxicity 
occurred (with the exception grade 3 nausea and vomiting without prophylactic anti-
emetics). A modification of 0.25 mg/m'/day was made if granulocytes';; 0.5 x 109/1 
and/or platelets,;; 50 xl 0 9/1 associated with infectionl bleeding or lasting between 
7-14 days; or if grade 2 non-hematological toxicity occurred. The minimum allowed 
infusion dose was 1.0 mg/m2/day. 
Evaluation 
Responses were evaluated according to the World Health Organisation (WHO) criteria 
(6). Response duration was defined from the initiation of treatment. The involved 
lesions were measured every two cycles. White blood cells (WBC) and platelets were 
determined biweekly during the first 2 cycles thereafter weekly. Blood chemistry 
tests including renal and liver functions and urinalysis were performed weekly. Toxicity 
was assessed every week according to the CTC criteria (7). 
RESULTS 
A total of 59 patients were entered in the study. Two patients were considered 
ineligible: one because there were no measurable lesions, the other because of prior 
chemotherapy for metastatic disease. These patients were excluded from all analyses. 
Patient characteristics are summarized in table 1. 
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Table 1. Patient characteristics 
No. of patients 
No. patients entered 59 
No. patients eligible 57 
Median age (range) 60 (34-74) 
Sex 
male 30 (53%) 
female 27 (47%) 
Performance status 
0 36 (63%) 
1 19 (33%) 
2 2 (4%) 
Prior therapy 
surgery 52 
radiotherapy 9 
adjuvant chemotherapy 2 
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The daily x 5 schedule was very well tolerated. There were 290 courses evaluable 
for toxicity. The median number of courses given per patient was 4 (range, 1-18). 
In 2 patients the administered dose had to be reduced: in one because of a sepsis 
during grade 4 neutropenia and in the other because of a grade 4 thrombocytopenia 
lasting for more than 7 days. Toxicities are listed in table 2. The major adverse reaction 
was myelosuppression. Leuco- and neutropenia occurred in more than 90 % of the 
courses, being grade 3-4 in respectively 48% and 79%. Despite the severe leuco-
neutropenia only 2 infectious complications were observed. Concurrent anemia and 
thrombocytopenia occurred frequently but were mild and of no clinical significance, 
with the exception of one grade 4 thrombocytopenia. There was no evidence of 
cumulative myelosuppression. 
Table 2. Drug related toxicities per course (n = 290) 
eTe 
1 2 3 4 
total % 
Leucopenia 25 113 106 21 265 91 
Neutropenia 20 33 117 90 263 91 
Anemia 119 119 6 244 84 
Thrombocytopenia 113 7 4 1 125 43 
Nausea 90 11 1 102 35 
Vomiting 21 8 29 10 
Asthenia, fatigue 69 16 1 86 29 
Alopecia (per pt.) 26 18 44 77 
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The non-hematologic toxicity was usually mild. Nausea and vomiting mainly occurred 
on the infusions days and could usually be easily circumvented with prophylactic 
use of standard anti-emetics, sometimes in combination with steroids. 
Four patients (7%; 95% CI 2-17%) achieved a PR, with a median duration of 11 
months (range 9.3 to 12.2), 32 patients had SO (56%) at evaluation whereas the 
remaining 21 patients had PD. 
DISCUSSION 
Despite the recent progress in cancer chemotherapy, metastatic colorectal cancer 
remains a frustrating issue in clinical medical oncology. The effect of systemic combi-
nation chemotherapy on the survival remains unclear. In addition, the cost-effectiveness 
of such therapy is debatable. Therefore it is essential to test the activity of new drugs, 
in an effort to improve the dismal outlook for patients with metastatic colorectal cancer. 
In the early 1970's camptothecin (CPT) demonstrated antitumor activity against 
gastrointestinal adenocarcinoma. Further clinical development was hampered because 
of unpredictable toxicity, notable severe myelosuppression, hemorrhagic cystitis and 
diarrhea. Topotecan is a new watersoluble semi-synthetic analogue of CPT. 
The present study shows that topotecan at this dose and schedule has only limited 
activity as a single agent therapy in colorectal cancer with a response rate of 7% 
with a median duration of 11 months. The number of patients with stable disease 
is noteworthy. The regimen was very well tolerated, with bone marrow suppression 
being the main toxicity. Although leuco- and neutropenia were very prominent, occurring 
in more than 90 % of the courses being grade 3-4 in about 50 %, infectious 
complications were seldom seen, probably because of the brief period of deep leuco-
penia. 
At this moment, irinotecan (CPT-11), another camptothecin analog shows more 
promising results in patients with metastatic colorectal cancer. Recently, several 
studies were published in patients with colore eta I cancer administrating CPT-11 at 
the dose of 125 mg/m2 every week x4, followed by a 2 week rest, showing a response 
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rate in un- and 5-FU-pretreated patients of 27-32% and 22-25% respectively (8-11). 
Topoisomerase" inhibitors exhibit marked schedule dependency. This may also be 
the case for topoisomerase I inhibitors such as topotecan. Preclinical data have indicated 
that topoisomerase I inhibitors demonstrate greater efficacy and have a greater 
therapeutic index with prolonged continuous exposure( 1 2, 13). The feasibility of the 
concept of prolonged exposure in humans using a 21-days continuous topotecan 
infusion repeated every 28 days was recently reported by Hochster et al. (14). In 
these pretreated patients the infusion was tolerated at a dose of 0.53 mg/m'/day, 
with dose-intensity exceeding other schedules of topotecan, except the bolus injection 
every 3 weeks. The dose limiting toxicity was also hematologic, with thrombocytopenia 
somewhat more profound than the to leucopenia. In view of the low numbers of 
responses we report with the daily-times-5 schedule in colorectal cancer, a study 
using prolonged infusion times seems warranted in this tumor type. 
In addition, recently reported results reveal a 32% bioavailability of oral topotecan, 
and thus oral administration may appear to be a more simple and convenient method 
for prolonged exposure and combination therapy with other cytotoxic agents (15). 
Phase I studies testing the feasibility of prolonged oral administration are ongoing. 
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SUMMARY 
Purpose: T opotecan is an inhibitor of topoisomerase I that has shown preclinical activity 
against different tumor types. Based on the results of a phase II study of topotecan 
as salvage therapy in ovarian cancer we conducted a large multicenter phase II study 
with topotecan as second-line treatment in ovarian cancer in patients who failed 
one platinum based chemotherapeutic regimen, to further evaluate and detail the 
efficacy and toxicity in this group of patients. 
Patients and Methods: Topotecan 1.5 mg/m2/day was administered intravenously 
by 30 minute infusion for 5 days repeated every 3 weeks. As the platinum-free interval 
is known to influence the response in subsequent treatment patients were stratified 
in subgroups, i.e. in platinum refractory, platinum resistant and platinum sensitive 
patients. 
Results: One-hundred eleven patients entered the study. Nineteen patients were 
considered to be ineligible, 92 patients were evaluable for response. A total of 552 
courses were given, with a median of 4 per patient (range 1-17). The major toxicities 
were leuco- and neutropenia, being grade 3-4 in 54.2% and 69.1 % of the courses 
respectively, but with only 4.3% of courses with grade 4 neutropenia and fever or 
infectious complications. Prophylactic G-CSF was given in 20.5% of the courses 
to maintain dose intensity. Other relatively frequent side effects were alopecia (82%) 
and mild nausea (36.4%) and vomiting (17.5%). The overall response rate was 16.3%, 
with 1 complete response and 14 partial responses. If expressed according to strata 
platinum refractory, platinum resistant and platinum sensitive the response rates 
were 5.9%, 17.8% and 26.7%, respectively. The median duration from time of 
documented response was 21.7 weeks (range 4.6-41.9). 
Conclusion: Topotecan in a daily x 5 schedule is an effective regimen as second-line 
treatment in ovarian cancer, with a favourable toxicity profile. Further investigations 
of topotecan in ovarian cancer including first line use and combination with other 
active agents are indicated. 
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INTRODUCTION 
Ovarian cancer is the most common cause of death among women with gynecologic 
malignancies. Its incidence is the highest in Europe and North America (1). Most 
ovarian tumors in the Western world are of the common epithelial type, accounting 
for nearly 90% of all ovarian malignancies. Many patients present with advanced 
stage disease. The mainstay of therapy for advanced stage ovarian cancer involves 
adequate surgical staging and cytoreduction followed by platinum-based chemotherapy, 
with initial response rates of 70-80% including a high portion of complete responses. 
However, the majority of patients eventually relapse and ultimately die of chemoresis-
tant disease (2). 
Response rates to salvage treatment are modest and the duration of response is usually 
relatively short. Recentlytaxanes were identified tohave second-line activity in ovarian 
cancer (3-11), but further studies on the optimal schedule of paclitaxel and 
circumvention of the side effects of docetaxel are necessary to properly define their 
potential in second-line treatment. Even then, it is clear that further new agents have 
to be identified for the salvage setting to hopefully improve the dismal outlook for 
patients with epithelial ovarian cancer. 
T opotecan ,[ (S) -g-dimethylaminomethyl-1 O-hydroxycamptothecinhydrochloride J)S 
a semisynthetic watersoluble analogue of the parent drug camptothecin. Topotecan 
is a specific inhibitor of the enzyme topoisomerase I, a cellular enzyme that is involved 
in maintaining the topographic structure of DNA. Topoisomerase I covalently binds 
to double-stranded DNA forming the cleavable complex which enables uncoiling of 
the DNA helix during replication and transcription resulting in transient single-strand 
breaks and relieves torsional strain along the fork of replicating DNA. Topoisomerase 
I inhibitors form a ternary complex with the covalently bound DNA-topoisomerase 
I enzyme and interfere with the DNA breakage and resealing process. It permits uncoiling 
of the double-stranded DNA but it prevents the resealing. The advancing replication 
fork then collides with the cleavable complex, resulting in fork breakage and eventually 
cell death (12-13). In preclinical testing topotecan has shown to have antitumor activity 
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against a variety of tumors including human ovarian xenografts (13-14). In phase 
I studies clinical antitumor activity was most clear in the daily x5 schedule with non-
cumulative neutropenia as the dose limiting toxicity. 
An initial phase II study using this schedule in 28 patients with ovarian cancer, of 
whom 80% were considered platinum-refractory, suggested activity for topotecan 
in this disease (15). The median number of prior chemotherapy regimens in these 
patients was 2 (range 1-4). The use of G-CSF to maintain dose intensity was prohibited 
in this study. 
The interval between prior platinum therapy and relapse is known to influence the 
response to subsequent therapy (16-18). This way, relapses can be discriminated 
in three groups: platinum-refractory disease, platinum-resistant relapse and platinum-
sensitive relapse. 
To properly define the efficacy of topotecan in a daily x5 schedule as a second-line 
treatment, in patients who failed one platinum based chemotherapeutic regimen, 
we performed a large phase II study taking these strata into account. 
PATIENTS AND METHODS 
Patients \ 
Patients with a histological diagnosis of epithelial ovarian cancer, FIGO stage III or 
IV at the time of entry into the study, who had failed first line therapy with one regimen 
containing cisplatin or carboplatin were eligible for the study. The population was 
defined by the following strata: 1. Platinum-refractory patients: Patients with progressive 
or stable disease while on initial platinum-based chemotherapy. 2. Platinum-resistant 
patients: Patients who responded and subsequently relapsed within 6 months after 
discontinuation of initial platinum-based chemotherapy. 3) Platinum-sensitive patients: 
Patients who responded but relapsed after more than 6 months after discontinuation 
of initial platinum-based chemotherapy. Eligibility further included; measurable disease 
must be ;;" 2 cm (in case of tumor measurement solely relying on physical examination, 
verification was to be performed by a second physician) ; age;;" 18 years; WHO 
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performance status" 2; adequate bone marrow function (white blood cells (WBC) 
;;" 3.5 x 10'/1, granulocytes;;" 1.5 x 10'/1 and platelets;;" 100 x 10'/1); serum creatinine 
" 132.6 pmol/l; serum bilirubin" 34.2pmol/l; serum SGOT(AST)/SGPT(AL T) and 
alkaline phosphatase" 2x the upper limit of normal, in case of liver metastasis" 
5x the upper limit; at least 4 weeks since last surgery, radiotherapy (indicator lesions 
must not be in the field of prior radiation) or chemotherapy; no active concomitant 
malignant disease, with the exception of adequately treated cone-biopsied in-situ 
carcinoma of the cervix and basal cell or squamous cell carcinoma of the skin; no 
prior treatment with taxanes; informed consent was obtained according to the local 
or national rules from all patients before entry of the study. 
Treatment schedule 
Topotecan 1.5 mglm'lday was administered as a 30 minute infusion for 5 consecutive 
days every 3 weeks. Topotecan (Hycamtin®) was supplied in vials as a light yellow, 
lyophilized cake. Each lyophilized vial contained 5 mg of the free base. The lyophilized 
formulation was reconstituted with 2 ml of sterile water for injection prior to dilution 
with 5% dextrose solution. The appropriate volume of the reconstituted solution 
was then further diluted in 50 ml 5% dextrose. 
Follow-up study scheme 
Complete blood count (CBC), blood chemistries including renal and liver functions, 
total protein, albumin and glucose were performed weekly. Urinalysis and determination 
of the CA-125 were performed before every cycle. An ECG was performed before 
treatment and prior to the second cycle. 
Dose modifications 
The next treatment cycle was administered if granulocytes were;;" 1.0 x 10'11 and 
platelets;;" 1 00 x 10'11. Prophylactic administration of G-CSF (Filgrastim®) 5 pg/kg 
subcutaneously injected once daily for 10 days beginning on day 6 of the treatment 
cycle could be started if the patient experienced grade 4 neutropenia and fever or 
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grade 4 neutropenia lasting;" 14 days or grade 3 neutropenia requiring a delay in 
the next cycle. A dose reduction of 0.25 mg/m2/day was performed if, with the addition 
of G-CSF, a grade 4 neutropenia was complicated by fever/infection or lasted ;" 
14 days, or if a grade 3 neutropenia lasted beyond day 21 of the treatment cycle. 
A dose reduction of 0.25 mg/m2/day was also performed if a grade 3-4 
thrombocytopenia was associated with bleeding or if thrombocytopenia grade 3-4 
lasted;" 14 days or if a grade 3-4 non-hematologic toxicity was seen. The single 
infusion dose was increased by 0.25 mg/m2/day if during the previous cycle there 
was no toxicity greater than grade 2. The minimum allowed infusion dose was 1.0 
mg/m2/day and the maximum allowed infusion dose was 2.0 mg/m2/day. 
Evaluation 
Responses were evaluated according to the World Health Organisation (WHO) criteria 
(19). All reported responses were confirmed by independent extramural review. The 
duration of stable disease (SD)' partial response (PR) and complete response (CR) 
was defined as the interval between the initial documented response to the first 
sign of progression. Measurement olthe involved lesions by computed tomographic 
scan, plain chest X-ray, and ultrasonography was performed every 2 cycles. Toxicity 
was assessed before every cycle according to the Common Toxicity Criteria (CTC)(20). 
RESULTS 
A total of 111 patients were entered into this phase II study. Nineteen patients were 
considered to be ineligible. Reasons for ineligibility were; more than one prior platinum 
based therapy (7), indicator lesions within the field of prior radiotherapy (5), no 
measurable disease (4), concomitant malignancy (1), surgery within 28 days before 
start treatment (1) and performance status> 2 (1). In order not to underestimate 
toxicity and overestimate efficacy an intention to treat analysis was performed including 
all entered patients. Ninety-two patients were formally evaluable for response. 
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Patient characteristics are summarized in table 1. These patients were stratified in 
3 subgroups, i.e. platinum-refractory (34 patients), platinum-resistant (28 patients) 
and platinum-sensitive relapses (30 patients). 
Table 1. Patient characteristics 
No. of patients 
No. patients entered 111 
No. patients eligible 92 
Mean age in years (range) 57.6 (25-76) 
Performance status (WHO) 
0 48 
39 
2 5 
Tumor size, em 
< 5 32 
;" 5 60 
Response to first-line therapy 
complete response 33 
partial response 25 
stable disease 16 
progressive disease 18 
Classification of relapse 
platinum refractory 34 
platinum resistant 28 
platinum sensitive 30 
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The majority of patients had bulky disease (tumor> 5 cm in diameter) and in addition 
to first-line platinum based chemotherapy 5 patients were pretreated with radiotherapy 
and 1 patient was previously treated with immunotherapy. 
For toxicity an intention to treat analysis was performed, including all patients. A 
total of 552 courses of topotecan were given, with a median number of 4 (range 
1-17) per patient. The major side effect was myelosuppression. Leuco- and neutropenia 
grade 3-4 occurred in 54.2 % and 69.1 %, respectively (table 2). The median nadir 
of neutropenia was 0.6 x 10'/1 (range 0.0-13.6) and was seen on day 11 (range 
2-29). The median duration of neutropenia was 7 days. Myelosuppression was not 
cumulative. Despite the severe neutropenia, fever;;::: grade 2 was observed in only 
4,3% of the courses with infectious fever in 3.1 % of cycles with grade 4 neutropenia, 
including one fatal neutropenic fever that occurred shortly after completion of the 
first treatment cycle. Treatment delays occurred in 25.4% of courses, delays lasting 
:;; 2 days in 10%,3-7 days in 11.8% and;" 7 days in 3.6% of courses. Hematological 
toxicity accountered for 14.5% of all treatment delays. G-CSF (Filgrastim ') was given 
in 20.5% of the courses, in 16.1 % itwas given prophylactically, in 4.3% of courses 
it was given as treatment. Dose reductions were very infrequent, only 6.8% of all 
courses were given at reduced doses, merely due to hematologic toxicity. On the 
contrary, 7.2% of the courses the dose of topotecan could be escalated (table 3).lf 
expressed as mean or median dose intensity (mg/m'/week) the targeted dose intensity 
of 2.50 mg/m'/week was achieved in 94.4% and 97.6% of the courses respectively 
(table 4). Thrombocytopenia was relatively mild, grade 3-4 thrombocytopenia was 
observed in 13.8% of the courses, with prophylactic platelet transfusions in 2.4%. 
Concurrent anemia, although easily manageable, was frequent; erythrocyte transfusions 
were needed in 20.7% of the courses (table 2). 
Non-hematological toxicities were mild and consisted of nausea, vomiting, stomatitis, 
fatigue and asthenia. Alopecia was seen in 82% of the patients being partial in 24.3% 
and total in 57.5% (table 5). 
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Table 2. Hematological toxicity per course (N 552) 
eTe grade grade 3 - 4 
1 2 3 4 % 
Leucopenia 56 123 245 52 54.2 
Neutropenia 26 68 156 218 69.1 
Thrombocyto- 237 68 44 32 13.8 
penia 
Anemia 154 312 56 5 11 . 1 
Table 3. Number of patients and courses per dose (mg/m2/day) 
Dose No. of No. of Course Course range 
(mg/m2/day) patients courses median 
1.00 4 5 1 1-2 
1.25 14 33 1 1-8 
1.50 111 474 3 1-17 
1.75 11 28 2 1-5 
2.00 5 12 1 1-5 
I Overall I 111 I 552 I 4 I 1-17 I 
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Table 4. Dose intensity (mg/m 2/week) per course 
Course n Mean Median 
1 111 2.31 2.50 
2 104 2.40 2.50 
3 79 2.48 2.50 
4 69 2.38 2.50 
5 53 2.45 2.50 
6 44 2.47 2.50 
7 27 2.47 2.50 
8 23 2.43 2.50 
9 11 2.46 2.50 
10 10 2.30 2.50 
11 5 2.50 2.50 
12 4 2.38 2.50 
13 3 2.50 2.50 
14 3 2.50 2.50 
15 3 2.50 2.50 
16 2 2.45 2.45 
17 1 2.50 2.50 
I Overall I 111 I 2.36 I 2.44 I 
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Table 5. Non·hematological toxicity per course (N 552) 
CTC 
1 2 3 4 total % 
Nausea 152 40 9 201 36.4 
Vomiting 60 30 7 97 17.5 
Fatique 61 19 80 14.4 
Stomatitis 44 26 2 1 73 13.2 
Asthenia 36 19 2 1 58 10.5 
Table 6. Response in relation to the interval of relapse after prior platinum based 
chemotherapy 
Relapse Refractory Resistant Sensitive 
No. pts 34 28 30 
CR 0 0 1 
PR 2 5 7 
SD 9 5 5 
total (%) 2 (5.9%) 5 (17.8%) 8 (26.7%) 
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Response data were analyzed in eligible patients. All responses were confirmed by 
independent review. None olthe responses were assessed by physical examination. 
The overall response rate was 16.3% (95% confidence interval (GI) 9.4-23.5%) with 
1 complete and 14 partial responses. If expressed according to the defined strata 
platinum-refractory, platinum-resistant and platinum-sensitive the response rates 
were 5.9%, 17.8% and 26.7%, respectively (table 6). In addition, 19 patients (20.7%) 
had stable disease. The median time to response was 10.4 weeks. The median response 
duration (measured from the time of first documented response) for the responders 
was 21.7 weeks (range 4.6-41.9). The median time to progression for all patients 
was 11.9 weeks. If the data were analyzed according to the intention-to-treat principle 
the overall response rate was 16 responses of 111 patients (14.4%; GI7 .9-20.9%). 
DISCUSSION 
Topotecan at this dose and schedule is active in ovarian cancer. The regimen was 
very well tolerated. Although neutropenia was very prominent, being grade 3-4 in 
69,1 % of the courses with a median nadir of 0.6 x 10911 (range 0.0-13.6), infectious 
complications (3.1 %) and treatment delays due to neutropenia (14.5%), with 
subsequently prophylactic administration of G-GSF (Filgrastim') occurred only in a 
minority of the courses. Dose reduction were rare and in addition, the targeted dose 
intensity was achieved in practically all courses. Presumably this reflects the brief 
duration of leuco- and neutropenia. Thrombocytopenia was much less common, and 
even grade 3-4 thrombocytopenia was never complicated by bleeding. 
Non-hematological toxicities were mild. Alopecia occurred in almost all patients, nausea 
and vomiting were easily circumvented with the use of standard anti-emetics, 
sometimes in combination with steroids. 
The present study showed that topotecan at this dose and schedule resulted in a 
response rate of 16.3% with a median duration of 21.7 weeks. In addition, 20.7% 
of patients had at least temporary stabilization of disease. This study that included 
92 patients, largely confirms the results of Kuldelka et al. (15) who obtained a response 
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rate of 14% with a median duration of 8.7 months, in a patient population of 28 
patients. In addition, these results fit with the recently published preliminary data 
of Armstrong et al. (21) with the daily x5 topotecan schedule as salvage therapy 
for ovarian cancer. They reported 1 complete and 3 partial responses in the first 16 
evaluable patients (25%), in a study for which accrual continues. 
If expressed according to the defined strata, platinum-refractory, platinum-resistant 
and platinum-sensitive, the observed response rates were respectively, 5.9%, 17.8% 
and 26.7%. So in truly platinum-refractory disease topotecan shows only modest 
activity. 
Many new drugs have been tested as salvage therapy in ovarian cancer in clinical 
trials; of these, especially the taxanes paclitaxel (Taxol) and docetaxel (Taxotere) 
seem promising (22). The obtained response rate with paclitaxel varies from 11.9-29% 
(3-8,23), and for docetaxel from 25-41 % (9-11,24). These results can not easily 
be compared with those of the present study since in many reports on taxanes the 
definitions of, and/or detailed information on the different strata is missing and for 
paclitaxel many different doses and infusion durations were applied. The European-
Canadian study (8) indicated that the efficacy of paclitaxel is more dose- than schedule 
dependent. Furthermore, prolonged infusions revealed more severe neutropenia, and 
as a consequence this resulted in more dose reductions. The latter study also included 
an independent response review and at the registered dose of 175 mg/m2 given over 
3 hours the response rate to paclitaxel was 15%, which is similar to the results 
presently reported for topotecan. In addition, increasingly paclitaxel is being used 
in the first line treatment of ovarian cancer which further stresses the need to develop 
new drugs with activity in second line such as topotecan. 
As compared to taxanes, and with the exception of shortlasting neutropenia, topotecan 
lacks, many side effects. Toxicities of taxanes include, alopecia, nausea/vomiting, 
mucositis, arthralgia/myalgia and anaphylactoid hypersensivity reactions. In addition 
paclitaxel induces peripheral neuropathy, and less frequently, cardiac dysrhythmias 
(3-8,23,25), while docetaxel induces skin toxicity, onycholysis and fluid retention, 
the latter two being related to the cumulative dose (9-11,23,25). 
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Although comparison of topotecan versus taxanes cannot be easily performed with 
the currently available data it is suggested that the efficacy might be in the same 
range and therefore a randomized study has been initiated to compare topotecan 
versus paclitaxeJ as second-line therapy in ovarian cancer. 
In an attempt to further improve the current results of topotecan in ovarian cancer 
other dosing schedules warrant exploration. Preclinical data have indicated that 
topoisomerase I inhibitors demonstrate greater efficacy and have a greater therapeutic 
index with prolonged continuous exposure (26,27). The feasibility of this concept 
of prolonged exposure in humans using a 21-days continuous infusion repeated every 
28 days is recently reported (28). The dose intensity exceeded most other schedules 
of topotecan. Phase II studies with this schedule in different tumor types, including 
ovarian cancer, are ongoing. In addition, recently reported results reveal a bioavailability 
of oral topotecan of 32% with limited variation, and thus oral administration may 
appear to be a more simple and more convenient method to achieve prolonged exposure 
(29). 
Combination therapy with cisplatin, the current most effective agent in ovarian cancer 
is of great interest because of the non-overlapping toxicities, the different mechanisms 
of action and the fact that topotecan potentially can interfere with repair from cisplatin 
induced DNA damage, a major mechanism of cisplatin resistance (30,31). The first 
dose-finding studies of this combination were recently be published (32,33), and 
other studies are on the way. 
In summary, topotecan at a dose of 1.5 mg/m'/day for 5 days repeated every 21 
days is an efficacious drug in ovarian cancer, with only relatively minor and readily 
managed, non-cumulative side effects. Future directions should include exploring 
alternative regimens and combinations with other agents active in ovarian cancer. 
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SUMMARY 
T opotecan is a novel semisynthetic derivative of the anticancer agent camptothecin 
and inhibits the intranuclear enzyme tapa isomerase I. The lactone structure of 
topotecan, which is in equilibrium with the inactive ring-opened hydroxy acid is essential 
for this activity. We performed a pharmacokinetic study, as part of phase II clinical 
trials in patients with various types of solid tumours with topotecan 1.5 mg/m'/day 
administered by a 30 minutes infusion for 5 consecutive days which was repeated 
every 3 weeks. Previously validated limited sampling models, using concentration 
measurements in samples obtained 2 hours after infusion, were used to calculate 
the area under the plasma concentration-time curves (AUGs) of both chemical forms. 
Samples were obtained from a total of 36 patients over 136 treatment days. The 
mean AUG of the closed ring form (AUG"" .. I was 8.74 JiMrnin/day (range 2.3- 16.3), 
and the mean AUG of the ring-opened form (AUG",") was 11.5 JiM min/day (range 
3.2- 46.0) (interpatient variability: 34 to 61 %). In each patient, the AUG-values achieved 
on the first day of administration were similar to, and thus predictive for, those achieved 
during the following days, with a day-to-day variation of 7.39% for the AUG",,,., 
and 12.6% for the AUG"",". There was no drug accumulation during the five consecutive 
treatment days of each cycle. However, despite the large interpatient pharmacokinetic 
variability, the importance of regular drug monitoring in this schedule can be questioned, 
as the pharmacodynamic variability was relatively small. 
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INTRODUCTION 
Topotecan ([SI-9-dimethylaminomethyl-1 O-hydroxy-camptothecin, SK&F1 04864, 
NSC 609699, Hycamtin®), is a semisynthetic derivative of camptothecin, an anticancer 
drug derived from the Asian tree Camptotheca acuminata. Due to camptothecin's 
serious and unpredictable gastrointestinal, urothelial and myelosuppressive toxicities, 
clinical evaluation had to be discontinued in the early 1970s (1 2, 13). Compared with 
camptothecin, topotecan as the hydrochloride salt is better water soluble, has a reduced 
protein binding and shows promising pre-clinical and clinical efficacy with a strongly 
reduced toxicity profile (7,9,15,25). The dose limiting toxicity of topotecan in phase 
I trials is reversible myelotoxicity, particularly granulocytopenia (15,16,18,24,25). 
The cytotoxicity of topotecan and other camptothecin analogues is ascribed to inhibition 
of the intranuclear enzyme topoisomerase I (1,8,19). The lactone structure, which 
is in equilibrium with the open-ring hydroxy acid (SK&F 105992) at constant pH is 
essential for this activity (figure 1) (7,26). 
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Figure 1: 
Chemical structures of topotecan (A) and its lactone ring-opened hydroxy acid (B). 
Both forms are in equilibrium at constant pH. 
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The closed lactone ring predominates at acidic pH, but the reverse reaction of the 
parent into the open ring form is favoured at physiological pH (2,4,21). The hydrolysis 
of the parent drug into the inactive form may thus have important pharmacokinetic 
and pharmacodynamic implications. 
The results of phase I clinical trials have suggested that pharmacokinetic parameters 
are well correlated with pharmacodynamic outcome (4,5,20,23,25). Especially the 
area under the plasma concentration-time curve (AUC) of topotecan was pre-eminently 
related to the degree of neutropenia and leucopenia (4,5,20,23,25). This relationship 
might be of value for the optimization of topotecan therapy since, by measuring the 
AUC, patients at high risk for developing serious toxicity might be identified at an 
early stage. Furthermore, the dose could in theory be adjusted upwards or downwards 
during a daily times five treatment to achieve the AUC associated with an optimal 
clinical outcome. However, since the topotecan dose in the phase I clinical trials 
was linearly related to the AUC (4,23,25), the escalation of the dose might have, 
consequently, defined predominantly the relationships between the AUCs and the 
toxicities. 
In order to find out whether this is true, we felt it important to further investigate 
the relationships between the AUCs and the toxicities in different subjects treated 
with a fixed topotecan dose. The Pharmacology And Molecular Mechanisms (PAMM) 
group and Early Clinical Trials Group (ECTG) of the EORTC (European Organization 
for Research and Treatment of Cancer) have recently taken the initiative to coordinate 
and stimulate pharmacokinetic studies as part of phase II clinical trials (14). The larger 
and more homogenous phase II patient population allows more insight into the variability 
in pharmacokinetics and their relationships with pharmacodynamics, such as toxicity 
and tumour response, as compared to phase I studies. We previously developed and 
validated a limited sampling model for topotecan (22) that can be used to get the 
necessary pharmacokinetic data with a minimum of samples taken from the patients. 
This limited sampling strategy was used for the present study in patients with ovarian, 
colorectal or small cell lung cancer (SCLC). Pharmacokinetic monitoring is also 
performed in other ongoing phase II studies coordinated by the EORTC-PAMM and 
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ECTG groups with the investigational anticancer agents irinotecan, docetaxel, E09, 
and rhizoxin (14). 
PATIENTS AND METHODS 
Patient population 
The patients participated in three phase II clinical trials in which topotecan was admi-
nistered daily at a dose of 1.5 mg/m2 for five consecutive days every three weeks. 
These phase II trials have recently been completed, and the detailed clinical results 
will be published elsewhere. Eligible were patients with ovarian cancer failing treatment 
with a platinum-based chemotherapeutic regimen, non-chemotherapy pretreated patients 
with colorectal cancer, or patients with small cell lung cancer (SCLC) failing or relapsing 
after first-line chemotherapy. All patients had an adequate bone marrow function 
(White Blood Cells (WBC) ., 3.5 xl 0'/1, absolute neutrophil count (ANC) ., 1.5 xl 09/1 
and platelets" 1 00 xl 0'/1), normal serum bilirubin (,; 26 pM) and serum creatinine 
('; 140 pM), no prior history of haemorrhagic cystitis, WHO performance status 
,; 2, life expectancy of ., 1 2 weeks and age 1 B- 75 years. All patients gave informed 
consent. 
Treatment plan 
Topotecan (Smith Kline Beecham, King of Prussia, USA) was supplied as a freeze-dried 
product, with topotecan as the hydrochloride salt (5 mg as free base) and 100 mg 
mannitol as bulking agent (Le. topotecan AA formulation). These vials were reconsti-
tuted before infusion with 2 ml of Water for Injection. The appropriate daily dosage 
of the drug was diluted in 50 ml of normal saline (NaCI 0.9%) and was administered 
intravenously by a syringe pump during 30 minutes. To assess the haematological 
and non-haematological toxicities, patients were evaluated each course by clinical 
history, physical examination, and serum chemistry. Haematology screen was performed 
twice weekly. Response was assessed every 2 courses. 
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Pharmacokinetic studies 
Blood samples (5 ml each) were taken by a venepuncture from a cubital vein, in the 
arm contralateral to the arm receiving topotecan. The blo'od samples were collected 
at one single time point: exactly at 2.5 hours after the start of the 30 minutes infusion. 
An error in sample timing of maximal 5 minutes was allowed. Each sample was collected 
in a heparinized tube at one and, when possible, at more days of drug administration. 
Plasma was obtained by immediate centrifugation (5 minutes; 1500'9) of the samples, 
which was followed by protein precipitation with cold methanol (-30° G); 1.0 ml plasma 
was added to 4.0 ml of methanol. Thereafter, the mixture was vortex-mixed and 
centrifuged (5 minutes; 1500'9), and the clear supernatant was transferred to a 
polypropylene tube and stored (-30° G) until analysis. The closed lactone ring and 
the lactone ring-opened form of topotecan were determined by a validated high 
performance liquid chromatographic (HPLG) method using fluorescence detection 
(2). The AUGs were calculated using the following validated limited sampling models 
(22), for the closed ring form: 
AUG""", (pM min) 499(min) . G2h(pM) 
+ 0.85(pMmin·m'/mg) . dose(mg/m'), 
and for the ring-opened form, 
AUG.p" (pM min) 551 (min) . G2h(pM) 
- 0.011(pMmin·m'/mg) . dose (mg/m'), 
where G2h is the plasma concentration of the closed or the ring-opened form, 
respectively, at 2 hours after the end of the 30 minutes infusion. The AUG of the 
lactone plus the ring-opened form (AUG,.to') was calculated by: AUG".,", + AUG.p,,' 
The intra patient (day-to-day) and interpatient variation in pharmacokinetics were 
calculated by analysis of variance (ANOVA). 
The pharmacodynamics, especially the myelosuppression, were explored using plots 
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of percentage decrease (%decr) in ANG, %decr in WBG and %decr in platelet count 
versus the AUG"",iday, the AUG""/day, the AUG",,,/day, and the total dose (mg). 
The percentage decrease (%decr) is defined as: 
%decr 
Pretreatment value - value of the nadir 
Pretreatment value·100% 
The data were fit to the respective sigmoidal maximum effect (sigEm~) models derived 
from the phase I clinical trial (23). Mathematically, these models are defined as: 
%decr = 
100·(p)H 
(P'O)H + (P)H 
where P is the value of the pharmacokinetic parameter or the dose, P,o the P that 
results in 50% decrease, and H is the Hill constant, which determines the shape 
of the curve. These values were for the %decr in ANG versus the dose(mg): H = 
2.27, P,o= 1.02; AUG""",: H = 1.55, P,o= 1.55; AUG,,,": H = 1.09, P60 = 1.97; 
and AUG"",: H = 1.30, P,o= 4.96 (23). The performance of these models for the 
phase II pharmacokinetic data was evaluated by using the relative Root Mean Square 
Error (%RMSE)-value (17). The %RMSE is a measure of precision and is defined as: 
N y, 
RMSE% = [N·'·~ (pe,)'] ·100% 
i= 1 
where N is e.g. the number of P-pairs (i.e. true with predicted values), and pe is the 
prediction error IIn(P 'ru",,~Hn(P "."" .. »). The smallerthe %RMSE, the better the relation 
is described by the model. To investigate the determinators of inter- and intraindividual 
kinetic variability, we correlated continuously-scaled patients characteristics with 
the pharmacokinetics by linear regression analysis. These characteristics were age, 
weight, height, creatinine clearance, and the number of topotecan courses received. 
The investigated pharmacokinetic parameters were the AUG"" .. /day, the AUG",,Jday, 
their ratio (AUG""'d/AUG",,1. and the AUG"",1day. These values were calculated 
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per day to account for the missing values during the five administration days. This 
is justified since the intra patient variability was very small « 1 5 %). Discontinuously 
scaled patient characteristics, such as gender (male versus female), WHO-performance 
status (0 versus 1 or 2), pretreatment status (prior chemotherapy or not), were also 
tested (Student's t-test) for differences in the values of the kinetic parameters. In 
addition, we investigated whether the kinetic parameters and/or patient characteristics 
were related to the toxicities by linear regression analysis and the Student's t-test, 
respectively. The computer program NCSS® (Number Cruncher Statistical System, 
Kaysville, Utah, USA, 1992) and Quattro Pro® (Borland International, Scotts Valley, 
CA, USA, 1992) were used for all calculations. 
RESULTS 
A total of 36 patients entered in this pharmacokinetic trial of which 18 patients (8 
female, 10 male) had colorectal cancer, 14 patients had ovarian cancer, and 4 patients 
(all female) had SCLC. All patients with ovarian cancer were pretreated with platinum-
containing chemotherapy, all patients with SCLC were relapsing after or failing first-line 
chemotherapy involving a variety of drugs, whereas the colorectal cancer patients 
had not received prior chemotherapy. The median age was 59 (range 48-75) years, 
the median performance status was 1 (range 0-2), and the median creatinine clearance 
was 80 (range 50- 112) ml/min. 
Toxicity 
In all 36 patients the major toxicity was granulocytopenia, with a mean %decr in 
ANC of 85% (48%- 99%) (being WHO-grade IV in 38/61 courses). Thrombocytopenia 
was much less frequent and less severe, with a mean %decr in platelet count of 
68% (range 45%- 99%) (being WHO-grade 3 in 5/61 courses and grade 4 in 2/61 
courses). Mild anaemia grade 1-2 occurred regularly, with a mean %decr in the 
haemoglobin (Hb) of 16% (range 4%-34%). The nadirs of both granulocytopenia 
and thrombocytopenia were between day 8 and 15, and were of short duration (3-5 
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days). Non-haematologic toxicities were grade II or less and included nausea, vomiting, 
diarrhoea, alopecia, fatigue, and stomatitis. 
Responses 
All patients were evaluable for response. Most patients (10/18) with colorectal cancer 
were progressive under topotecan treatment. However, one patient had a partial 
remission, and seven patients remained stable for at least 2 months. Of the ovarian 
cancer patients 1 achieved a complete remission, 2 a partial remission, 7 were stable, 
and 4 progressive. Two patients with SCLC remained also stable, while the two others 
progressed. 
Feasibility 
It appeared that the requirements for the sample acquisition were generally very 
demanding for the clinical staff; the sample had to be timely withdrawn at exactly 
2 hours after the end of infusion, which had to be followed by immediate centrifugation 
and careful volumetric pipettation into cold and volatile methanol, whereafter 
centrifugation was required again, followed by refrigeration and finally shipment to 
our laboratory. In addition, it appeared that patients treated on an outpatient·basis 
were frequently not willing to wait for the blood sampling at 2 hours after infusion. 
For these reasons, despite the fact that over 200 patients entered the full phase 
II programmes in over 30 institutions, pharmacokinetic samples could only be obtained 
from two institutes in the Netherlands over 136 treatment days, in 61 courses. 
Pharmacokinetics 
Intrapatient data 
The AUC-values for the first day of administration were similar to and thus predictive 
for those achieved in the following days in the same patient (n = 1 9 patients), with 
a day-to-day variation of 9.7% for the AUC""" 12.6% for the AUC,,,,, and 7.39% 
for the AUC"".,. Thus, no accumulation of topotecan occurred during the consecutive 
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days of administration. Furthermore, the intrapatient variability between courses was 
also small (n = 10 patients, 39 courses), with a course-to-course variation ranging 
between 9.4% to 10.7%. 
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Figure 2: 
Frequency plot of the mean AUC"", per patient. 
Interpatient data 
However, a wide interpatient (n = 36 patients) variability in the pharmacokinetics 
of topotecan was found, being 39.3% for the AUC"", (Figure 2), 60.9% for the AUC""", 
and 34.4% for the AUC"",d' The mean AUC of topotecan was 8.71 pM min/day 
(range 2.3-15.8), and the mean AUC of the ring-opened form was 11.49 pM min/day 
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(range 3.2-46.0). The ratios of the AUG"," and AUG""'d ranged between 0.15 and 
1 .96, with a mean ratio of 0.91. The value of this ratio was patient-dependent (inter-
patient variation 67.2%), with a day-to-day (intrapatient) variation of 10.1 %. The 
patients with ovarian cancer appeared to have higher AUCclosed and AUCtota(levels 
than patients with colorectal cancer (0.00001 < p < 0.006). Patients with SGLG had 
lower AUG-levels than patients with colorectal cancer, but this was not statistically 
significant (0.06 < p < 0.35; n = 4). Other parameters, such as age, weight, height, 
gender, creatinine clearance, performance status, or the number of topotecan courses 
received were not significantly related with the kinetic parameters (Table 1). 
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Table 1 Relationships between patient characteristics and pharmacokinetic parameters 
Patient Characteristic AUCclosed AUCopen AUCtota, AUCclosed/AUCopen 
r p-value r p-value r p-value r p-value 
Patients with ovarian cancer 
Age 0.21 0.45 0.19 0.06 0.03 0.04 0.40 0.06 
Creatinine clearance 0.03 0.01 0.02 0.07 0.01 0.55 0.04 0.92 
Height 0.16 0.26 0.28 0.07 0.27 0.07 0.16 0.41 
Number of courses received 0.17 0.45 0.13 0.51 0.01 0.35 0.33 0.35 
Weight 0.18 0.68 0.07 0.04 0.03 0.05 0.14 0.30 
Performance Status 0.14 0.43 0.20 0.42 
Progression vs no progression 0.02 0.008 0.006 0.50 
Patients with colorectal cancer 
Age 0.15 0.88 0.24 0.32 0.21 0.37 0.44 0.18 
Creatinine clearance 0.02 0.99 0.16 0.65 0.15 0.67 0.17 0.33 
Height 0.10 0.21 0.15 0.73 0.16 0.62 0.03 0.98 
Number of courses received 0.08 0.01 0.05 0.01 0.06 0.01 0.08 0.01 
Weight 0.17 0.91 0.07 0.67 0.09 0.71 0.06 0.70 
Gender 0.64 0.17 0.56 0.16 
Performance Status 0.87 0.47 0.48 0.78 
Progression vs no progression 0.48 0.47 0.41 0.99 
Abbreviations: AUC: area under the concentration-time curve of the lactone from (closed). the ring-opened form (open). and 
the sum of both (total), respectively; r: correlation coefficient; -: not applicable (Student's t-test only); vs: versus 
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Pharmacokinetic-Pharmacodynamic relationships 
The mean AUG""."day, AUGoP'o/day, the AUG"",/day, and the total dose/day (mg) 
were plotted against the %decr in WBG, the %decr in ANG and the %decr in platelets. 
The sigmoidal Em" models previously derived from the phase I clinical trial (23), were 
used to describe the data and evaluated for their precision. For example, plots of 
the toxicity versus the dose (mg) could not adequately be described by the previously 
defined sigmoidal Em" model (RMSE% > 35%). This is in contrast to plots of the toxicity 
versus the AUGs of the ring-opened form, the closed ring form, and the sum of both, 
which were well described by their respective sigmoidal Em" models. Especially plots 
of the %decr in ANG, which was the most prominent side-effect, versus the AUGs 
fitted adequately to the previously defined sigmoidal models, with RMSE%-values 
ranging from 12.0% to 13.5% (Figure 3). These values were not significantly different 
from the RMSE%-values found in the phase I study (p> 0.05). For the %decr in platelets 
and %decr in WBG, the RMSE%-values ranged from 18.3% to 19.1 % and from 25.1 
to 25.6%, respectively. Besides the AUG-values, other predictive parameters for 
the %decr in ANG were the number of topotecan courses received (r=0.42, p =0.001), 
and the performance status (p = 0.022). There were no relationships between the 
grade of the non-haematological toxicities and the investigated patient characteristics 
or pharmacokinetic parameters. The number of responses was to small to allow a 
statistically meaningful analysis of relationships between response and the AUGs 
or other parameters. 
DISCUSSION 
The toxicities of topotecan in this 1.5 mg/m'/day daily times 5 schedule are similar 
to those reported in the phase I (4,23,24) and II (10,11) clinical trials using this 
schedule. Myelosuppression, especially granulocytopenia was most prominent, with 
62% of the pharmacokinetically monitored courses resulting in a grade 4 neutropenia. 
Also the pharmacokinetics and their relationships with the pharmacodynamics were 
similar, despite the use of a fixed dosage in this study. The plots of the %decr in 
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ANC versus the AUCs could adequately be described by the sigmoidal Em" models 
that were originally fitted to the data reported for the preceding phase I clinical trial 
(Figure 3) (23). In that study, we predicted from the fitted models that a fixed dose 
of 1.5 mg/m'/day administered in phase II studies would result in an average %decr 
in ANC of 87%, which is in good agreement with the %decr of 85% found in the 
present study. 
The closed ring structure is assumed to be essential for cytotoxic activity (6,7). Since 
the ratios of the AUC"",,,, and AUC""" varied between 0.15 and 1.96, and were patient-
dependent, patients with equal AUC"",-values have been exposed to different concen-
trations of the lactone form. However, either the AUCSC10Sedl AUCsopenl or AUCSto,a, 
were equally related to the haematological toxicity, which is also in agreement with 
the phase I clinical trial (23). Thus, it may seem that the fraction of topotecan present 
in plasma as the active lactone form is not that important for the toxicity. This may 
be explained by the reversibility of the conversion of the closed ring form into the 
ring-opened form; the open ring might spontaneously close to form the lactone form 
at the target under the right conditions. This hypothesis is supported by the fact 
that the parent compound camptothecin originally was administered as the sodium-salt 
of the ring-opened carboxylate form, and was also toxic and active (3,12,13). However, 
it is still advisable to administer topotecan dissolved in an acidic infusion fluid to 
yield the closed ring form. The closed ring form has the largest volume of distribution 
(4,23), indicating that this form is better distributed over the body, which may be 
important for higher tumour penetration. Unfortunately, because of limited numbers 
in the present study a statistically meaningful relationship between the AUCs and 
response was not present. It is, however, interesting to note that progressive patients 
with ovarian cancer had higher AUC-values compared to patients who remained stable 
or the few that responded to therapy. If this could be confirmed in larger numbers 
of patients, it suggests that the contribution of the drug exposure (AU C) to the tumor 
response is minimal at the fixed phase II dosage. 
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Then it is likely that other, tumor-dependent factors, such as type and amount of 
topoisomerase I levels, the number of cells in S-phase and the expression of P-
glycoprotein (19), are more important for antitumor effect. 
The variability in the ratio of the AUC""" and AUC"," that was found in the present 
study may be explained by the differences in the pH of the administered infusion 
fluid. Measurement of the pH in the NaCI 0.9% containing infusion fluid of several 
patients yielded pH-values between 3.5 and 6.1, indicating that different fractions 
of the drug present as lactone form were administered. Similar results were reported 
by Grochow et al.(4) for topotecan added to 5% dextrose infusions. For future studies 
with topotecan, however, it is expected that the variability in the AUC""., and AUC",," 
will be much less, since the AA formulation as used in the present study has now 
been replaced by the ACI AF formulation containing tartaric acid to increase the stability 
of the lactone form. 
Measurements of the pH of these infusions indicated that 100% of the drug is present 
in the lactone form during infusion (pH< 3.5), which we confirmed by HPLC analysis. 
In general, therapeutic drug monitoring is beneficial for toxic drugs that display a 
high pharmacokinetic variability and a high pharmacodynamic variability, in combination 
with a good relationship between the two. For topotecan, the difference in AUCs 
varied up to 10-fold between patients, but resulted in only a small interindividual 
difference in toxicity. This can be explained by the use of the maximum tolerable 
dose of topotecan in this phase II study producing AUCs generally being more than 
15 JIM min, which is associated with maximum toxicity (%decr in ANC around 85%) 
and therefore small variability. As the pharmacodynamic variability was relatively 
small, it seems questionable whether regular drug monitoring of topotecan in this 
schedule will be valuable to account for differences in toxicity or response. 
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SUMMARY 
Purpose: Topotecan is a specific inhibitor of topoisomerase I. Preclinical data have 
indicated that topoisomerase I inhibitors demonstrate more efficacy and have a greater 
therapeutic index with prolonged continuous exposure. The feasibility of this concept 
in humans using a 21-days continuous infusion with topotecan has been reported. 
We conducted a phase II study with this 21-days continuous topotecan administration 
in patients with locally advanced, irresectable, or metastatic colorectal cancer. 
Patients and Methods: Topotecan 0.6 mg/m'/day was administered as a continuous 
infusion via an ambulatory pump for 21 days repeated every 4 weeks. The starting 
dose was reduced to 0.5 mg/m'/day because in 5 of the first 11 patients the second 
course had to be delayed. Fourty-two patients entered the study, 1 patient was ineligible 
and was excluded from further analyses. 
Results: The overall response rate was 10%, with 1 complete and 3 partial responses. 
The median duration of response was 7 months (range 4-11). With this schedule 
the major toxicity was prolonged cumulative myelosuppression with a striking inhibition 
of the erythropoiesis. Other side effects were mild, including alopecia (47%), periodic 
nausea (40%)/vomiting (22%) and fatigue (16%). Pharmacokinetics revealed a mean 
Css of topotecan of 0.62 ng/ml (range 0.33-1 .1) with a significant relationship between 
Css of topotecan and CTC-grade of leucopenia. 
Conclusion: Topotecan administered as a 21-days continuous infusion exerts modest 
activity as single agent therapy in patients with metastatic colorectal cancer. 
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INTRODUCTION 
Colorectal cancer is one of the most common malignancies in the Western countries. 
The primary treatment is surgical resection but approximately half of the patients 
will eventually die of metastatic disease. Over the last 20 years 5-fluorouracil (5-FU) 
remained the mainstay of systemic treatment in patients with metastatic colorectal 
cancer, with reported response rates ranging from 5-20%, responses usually being 
of short duration. Biomodulation with folinic acid, interferons, methotrexate (MTX) 
or phosphonacetyl-L-aspertate (PALA) induces higher response rates, but complete 
responses are rare and the impact on survival is marginal (1-3). 
Thus, the poor prognosis for patients with metastatic colorectal cancer and the lack 
of essential progress in this common disorder is a continuous impulse to test new 
drugs for their activity in this disease. 
Topotecan, (S)-9-dimethylaminomethyl-1 O-hydroxycamptothecin is a watersoluble 
analogue of camptothecin (4,5), a plant alkaloid from the decidous tree Camptotheca 
acuminata. Topotecan exerts its cytotoxic activity during the S-phase of the cell cycle 
through specific inhibition of the enzyme topoisomerase I. T opoisomerase I relaxes 
the supercoiled DNA by forming a covalent adduct with DNA, known as the cleavable 
complex, resulting in transient single strand breaks through which the intact strand 
is allowed to pass. DNA relaxation occurs from swivelling at this nick and so plays 
an important role in DNA replication and RNA transcription. The enzyme breaks are 
then resealed by topoisomerase I (relegation). Binding of topoisomerase I inhibitors 
to the cleavable complex permits uncoiling but prevents relegation in presence of 
the drug. Cytotoxicity occurs by interaction of the advancing replication fork with 
the drug-trapped cleavable complex, resulting in fork breakage and eventually cell 
death (6,7). 
It has been shown that colon cancer cells contain a fivefold higher level of 
topoisomerase I than adjacent normal tissue (8) and preclinical data have indicated 
that topoisomerase I inhibitors demonstrate greater efficacy and have a greater 
therapeutic index with prolonged continuous exposure (9,10). Hochster et al. (11) 
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recently reported a phase I study pursuing prolonged exposure to the drug using 
a 21-days continuous infusion repeated every 28 days. In pretreated patients the 
infusion was tolerated at a dose of 0.53 mg/m'/day. The dose limiting toxicity was 
myelosuppression, with thrombocytopenia somewhat more profound compared to 
neutropenia. Responses were reported in tumor types that are usually considered 
resistant to chemotherapy. 
In view of these data, we conducted a phase II study with topotecan administered 
as a 21-days continuous infusion repeated every 28 days in patients with metastatic 
colorectal cancer. 
PATIENTS AND METHODS 
Patients 
Patients at least 18 years of age with histologically confirmed, locally advanced, 
irresectable, or metastatic colorectal cancer, who had not received any previous 
chemotherapy for metastatic disease were enrolled in the study. All patients had 
at least one bidimensional lesion and were suitable and willing to have a permanent 
medi-port device. A WHO performance status of " 2 and a life expectancy of ;" 
3 months was required. In patients who had received adjuvant chemotherapy, the 
treatment-free interval had to be a minimum of 1 2 months. Prior radiotherapy was 
allowed if the interval was;" 4 weeks. Eligibility further required: adequate bone 
marrow function (white blood cells (W8C) ;" 3.5 x 10'/1, granulocytes;" 1.5 x 10'/1 
and platelets;" 100x 10'/1); creatinine" 135pmol/l; serum bilirubin" 30pmol/l, 
serum ASAT/ALAT " 2x the upper limit of normal, in presence of liver metastasis 
" 5x the upper limit. Informed consent was obtained according to institutional rules 
before entry into the study. 
Treatment schedule 
Topotecan 0.6 mg/m'/day was administered as a 21-days continuous infusion repeated 
every 28 days. Topotecan (Hycamtin') was supplied in vials as a light yellow, lyophilized 
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cake. Each lyophilized vial contained 5 mg of the free base. The lyophilized formulation 
was reconstituted with 2 ml of bacteriostatic water for injection, preserved with benzyl 
alcohol. The appropriate volume of the reconstituted solution was transferred to the 
cassette. Final dilution to a total volume of 50 ml was made at a concentration such 
that the total daily dose was contained in every 6 ml of solution. The cassette was 
inserted in a CADD-PLUS ambulatory infusion pump (Pharmacia-Deltec Inc., St. Paul, 
USA) adjusted at a flowrate of 6 ml per 24-hours and connected to the medi-port 
device. Stability data for the topotecan solution have been generated for at least 
8 days under the conditions used in the study. Cassette and batteries were changed 
every week. 
Dose modifications 
The next treatment cycle was administered if granulocytes were;;' 1.0 x 109/1 and 
platelets;;, 100 x 109/1. The dosage of topotecan was reduced by 0.1 mg/m'/day 
if myelosuppression persisted beyond day 28 or if the previous cycle of topotecan 
was prematurely stopped because of grade 4 myelosuppression. If toxicity was grade 
2 or lower, the dose of topotecan was increased by 0.1 mg/m'/day. 
Pretreatment and fol/ow-up study scheme 
History, physical examination and assignment of toxicity, according to the Common 
Cytotoxicity Criteria (CTC) were performed every week (12). Complete blood cell 
counts (CBC) including differential were performed twice weekly. Blood chemistries 
including electrolytes, renal and liver functions, total protein, albumin and glucose 
were obtained weekly. Urinalysis was performed before every cycle. An ECG was 
performed before treatment and prior to the second cycle. 
Evaluation 
Responses were evaluated according to the World Health Organisation (WHO) criteria 
(13). Response duration was defined as the interval between the initiation of treatment 
to the first sign of progression. Measurement of the involved lesions by computed 
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tomographic scan, plain chest X-ray or ultrasonography was performed every 2 cycles. 
Pharmacokinetics 
Heparinized blood samples (2.8 ml) were collected during cycle 1 on day 2, 8 and 
15 and during cycle 2 on day 8 to determine the steady-state plasma concentration 
(Css) of topotecan and the ring-opened product hydroxy-acid. After collection, the 
blood samples were centrifuged immediately for 5 minutes at 3500 rpm, 250 pi of 
the plasma was immediately transferred to a polypropylene tube containing 750 pi 
of cold methanol (-20°C) and mixed on a whirl mixer for 15 seconds. Subsequently, 
the sample was immediately stored at -80°C until analysis. T opotecan and the hydroxy-
acid were analyzed simultaneously with a reverse phase HPLC system and fluorescence 
detection as described by Laos et al. (14), with a lower limit of quantification (LLQ) 
of 0.1 nglml for both compounds. The spearman rank correlation coefficient was 
calculated between the Css and toxicity parameters. 
RESULTS 
A total of 42 patients were entered in the study. One patient was considered ineligible 
because there was no histologic confirmation of the colorectal cancer. This patient 
was excluded from all analyses. Another patient was not evaluable because of the 
development of an intra-abdominal abscess and colo-cutaneous fistula in the first 
week after initiation of therapy, for which reason treatment was discontinued. Patient 
characteristics are summarized in table 1. 
Although a 21-days continuous infusion is rather inconvenient for patients treatment 
was well tolerated. In 4 patients treatment was complicated by thrombosis of the 
subclavian vein at the site where the medi-port device was inserted. In 3 patients 
this was the first sign of progression. Two patients experienced a local infection 
of the medi-port device; with an early start of antibiotics the device was preserved. 
Fourty patients were assessable for toxicity and response and received a total of 
142 courses. The median number of courses given per patient was 3 (range 1-14 +). 
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No. patients entered 
No. patients 
evaluable 
ineligible 
Sex 
Age 
male 
female 
median 
range 
Performance status 
o 
1 
2 
Prior treatment 
prior surgery 
Table 1: Patient characteristics 
prior surgery and prior radiotherapy 
prior surgery and adjuvant chemotherapy 
no prior treatment 
Metastatic sites 
lung 
liver 
lymph nodes 
miscellaneous 
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No. of patients 
42 
41 
1 
20 
21 
57 
38-69 
14 
25 
2 
27 
3 
3 
8 
11 
26 
11 
12 
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The starting dose was reduced from 0.6 mg/m'/day to 0.5 mg/m'/day after the second 
course had to be delayed in 5 of the first 11 patients because of prolonged 
myelosuppression. The main toxicity was myelosuppression, with neutropenia grade 
3-4 in 20 % of the courses with the median nadir ANC observed on day 25 (range 
8-25); Thrombocytopenia was mild, being grade 3-4 in only 8 % of the courses, 
and the platelet nadir also occurred on day 25 (table 2). 
Table 2: Drug related toxicity per course (n 142) 
eTe grade 
grade 3-4 
1 2 3 4 % 
leucopenia 22 2 17 
neutropenia 17 11 20 
thrombocytopenia 8 4 8 
anemia 250 units of erythrocyte transfusions were needed to 
keep the hemoglobin > 6.0 molll 
nausea 52 5 40 
vomiting 25 6 22 
fatigue 20 3 16 
alopecia (per pt.) 13 6 47 
Despite the mild myelosuppression treatment had to be delayed in 26 % of the courses 
due to prolonged myelosuppression. Following treatment delays the protocol mandated 
a dose reduction in the subsequent course. 
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Related to this, the mean dose intensity (mg/m'/week) decreased from 2.65 to 1.43 
mg/m'/week (figure 1), illustrating that the myelosuppression was cumulative. In 
addition, a marked inhibition olthe erythropoiesis was observed. A total of 250 units 
of erythrocyte transfusions were needed to keep the hemoglobin (Hb) > 6.0 mmol/I. 
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Figure 1: 
Graph showing the gradually decreasing mean dose intensity ± SD (mg/m'/week) 
per treatment course. 
Non-hematologic side effects were alopecia (47%) being grade 1 in more than two-third 
of the patients, mild periodic (often only in first week of treatment) nausea (40%) 
and vomiting (22%), asthenia/fatigue (16%). 
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The latter was partially associated with anemia as symptoms subjectively reduced 
after transfusion. 
Steady-state (Css) levels of topotecan could be determined in 37 patients and varied 
widely; 0.62 ± 0.17 nglml (range 0.33-1.1) (table 3). A low but statistically significant 
correlation was found between Css and CTC grade of leucopenia (R =0.54, p = 0.001). 
There was no correlation between Css and the absolute dose of topotecan. 
Four patients achieved a response (10%), including 1 complete response lasting for 
8 months and 3 partial responses with a duration of respectively, 4, 7 and 11 months. 
Seventeen patients had stable disease (43%) at evaluation whereas 19 patients had 
progression (47%). 
Table 3: Pharmacokinetics of Topotecan and Topotecan plus hydroxy-acid 
Pharmacokinetic 
parameter 
Css (ng/mL)' 
mean (SD) 
range 
CL (l/min) 
mean (SD) 
range 
n = 37 
Topotecan 
0.62 (0.17) 
0.33 - 1.1 
1.14 (0.33) 
0.63 - 2.04 
Topotecan + HA 
1.94 (0.47) 
1.23 - 3.02 
0.35 (0.08) 
0.24 - 0.54 
HA, hydroxy-acid; Css, steady-state plasma concentration; CL, clearance 
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DISCUSSION 
This phase II study in patients with locally, irresectable or metastatic colorectal cancer 
was initiated based on previous data of Hochster et al. (11) who reported favourable 
responses using a 21-days continuous infusion of topotecan via an ambulatory pump 
repeated every 28 days, pursuing the prolonged exposure that in vitro has shown 
to possess more cytotoxic activity and may have a greater therapeutic index (9,10). 
In the heavily pretreated patient population of that phase I study topotecan was 
tolerated at a dose of 0.53 mg/m'/day, the dose-limiting toxicity was myelosuppression 
with thrombocytopenia somewhat exceeding leucopenia. Seven objective responses 
were observed including tumor types usually considered chemotherapy resistant. 
Although no responses were seen in patients with colorectal cancer this was imputed 
to the factthalthose patients were mainly entered atthe lower dose levels (personal 
communication). The starting dose of the presently reported study was 0.6 mg/m'/day 
as our patients hardly received prior chemotherapy, but the starting dose had to be 
reduced to 0.5 mg/m'/day after in 5 of first 11 patients the second course had to 
be delayed. Overall, the magnitude of myelosuppression was less pronounced, 
presumably because patients had not received prior chemotherapy, but the recovery 
from myelosuppression was delayed and therefore treatment had to be postponed 
in 26% of the courses. In addition, we demonstrated that the myelosuppression was 
cumulative, with a mean dose intensity gradually decreasing from 2.65 to 1.43 
mg/m'/week. Furthermore, we observed a marked inhibition of erythropoiesis. In 
vitro data have shown that topoisomerase inhibitors added to bone marrow cultures 
impair the formation of early BFU-E derived colonies, late CFU-E derived colonies 
and mixed hemotopoietic (CFU-GEMM derived) colonies in a time and concentration 
dependent fashion. Topoisomerase inhibitors also impair the maturation of erythroblasts 
by inhibition of the hemoglobinization (15). Contrasting preclinical data, the efficacy 
of the 21-days infusion in patients with colorectal cancer was modest with an overall 
response rate of 10% (1 CR and 3 PRs) with a median duration of 7 months (range 
4-11). 
103 
Chapter 6 
The low correlation coefficient of 0.54 between Css and the CTC-grade of leucopenia 
illustrates that the pharmacokinetic variability is not a major determinant of this toxicity. 
Clinical studies with irinotecan (CPT-11), another topoisomerase I inhibitor reveal 
more promising results in patients with metastatic colorectal cancer. Several are 
published administrating CPT-11 at a dose of 125 mg/m2 every week x4, followed 
by a 2 weeks rest, showing a response rate in chemonaive patients of 27-32% and 
in 5-FU-pretreated patients of 22-25% (16-19), but severe (grade 3-4) diarrhea, despite 
the early and frequent use of loperamide, remains an important side effect. 
Despite the rather disappointing'results on efficacy in this study, the concept of 
continuous exposure should not be refuted. A 21 day exposure may show to be 
efficacious in more sensitive tumor types, and for relatively resistant tumor types 
such as colorectal cancer a better balance between the necessity of achieving higher 
plasma concentrations without coinciding excessive toxicity may be obtained by 
shorter infusion durations. In addition, in view of the reported 32% bioavailability 
of oral topotecan (20) and the patient convenience related to oral dosing, prolonged 
topotecan administration by oral application should further be studied. 
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SUMMARY 
Background and purpose: Results of preclinical and clinical studies indicate enhanced 
antineoplastic activity of topotecan (SKF 104864-A) when administered on a chronic 
treatment. We determined the apparent bioavailability and pharmacokinetics of 
topotecan administered orally to 12 patients with solid tumors in a two-part crossover 
study. 
Patients and methods: The oral dose of 1.5 mg/m' was administered as a drinking 
solution of 200 ml on day 1. The i.v. dose of 1.5 mg/m' was administered as a 30 
minute continuous infusion on day 2. The bioavailability was calculated as the ratio 
of the oral and i.v. AUC calculated up to the last measured time point. 
Results: The oral drinking solution was well tolerated. The bioavailability revealed 
moderate interpatient variation and was 30% ± 7.7% (range 21-45%). The time 
to maximal plasma concentration after oral administration (Tmax) was O. 78 hr (median; 
range 0.33-2.5). Total i.v. plasma clearance of topotecan was 824 ± 154 ml/min 
(range 535-1068 ml/min). The AUC ratio of topotecan and the lactone ring-opened 
hydrolysis product (hydroxy-acid) was of the same order after oral (0.34-1 .13) and 
i.v. (0.47-0.98) administration. 
Conclusions: The bioavailability of topotecan after oral administration illustrates 
significant systemic exposure to the drug, which may enable chronic oral treatment. 
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INTRODUCTION 
T opotecan, (s)-9- dimethylaminomethyl-1 O-hydroxy-camptothecin is a semisynthetic 
watersoluble analogue of camptothecin (1). Like camptothecin, topotecan is a specific 
inhibitor of topoisomerase I (1). Topotecan incorporates a stable basic side chain 
at the 9-position of the A-ring, which provides water solubility at acid pH. Topotecan 
is converted to its lactone ring opened hydrolysis product (hydroxy-acid), which 
reversible pathway is strongly pH dependent. The biologic activity of the hydroxy-acid 
has not fully been elucidated (2). Antitumor activity has been demonstrated in preclinical 
models and in phase I and II studies (3-9). The results of preclinical and clinical studies 
indicate enhanced antineoplastic activity of topotecan when administered daily for 
prolonged periods of time (4,7,8,10-12). Also, preclinical studies with oral topotecan 
have shown efficacy against rhabdomyosarcoma and coloncarcinoma in mice (1 2). 
The unique mechanism of action and lack of cross resistance evidence with many 
well known currently available antitumor agents may provide therapeutic advantage 
in first line or second line chemotherapy. Furthermore, combination therapy of topotecan 
and other available antineoplastic agents may well be advantageous (13, 14). In view 
of the data suggesting the importance of prolonged exposure to topotecan for better 
antitumor activity and the impracticality to achieve this exposure by intravenous 
administration an oral formulation is being developed. 
In the present study the bioavailability and pharmacokinetics of oral topotecan are 
explored in patients with solid tumors with the aim to provide a basis for further 
development of clinical studies utilizing chronic oral topotecan. 
PATIENT SELECTION, MATERIALS AND METHODS 
Patient selection and treatment schedule 
All patients gave written informed consent according to local regulatory requirements. 
Eligibility for the clinical study required a pathologically confirmed small cell lung 
cancer, colon cancer or ovarian cancer refractory to standard therapy or for which 
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cancer type no therapy of proven benefit exists. The performance status had to be 
,;; 2 on the WHO scale and life expectancy", 3 months. The minimal age had to 
be 18 and maximal age 75 years. The hemoglobin had to be "' 6.0 mmolll (9 g/dl), 
WBC "' 3.5x 10'/1, granulocytes", 1.0x 10'11 and platelets", 1 OOx 10'11. The serum 
creatinine had to be ,;; 140 pmol/l (1 .6 mg/dl), the serum bilirubin ,;; 26 pmol/l (1 .5 
mg/dl) and alkaline phosphatase and transaminases ,;; 2 times the upper normal limit 
or ,;; 5 times the upper limit of normal if liver metastases were present. 
Topotecan was administered orally and intravenously at a dose of 1.5 mg/m2 • Topotecan 
as supplied for intravenous infusion was diluted for oral dosage. Each 5 mg vial of 
topotecan was reconstituted with 10 ml 5% dextrose injection solution to give a 
0.5 mglml solution of the drug. The dose was placed in a beaker containing 100 
ml of 5% dextrose injection solution. On day 1, patients were asked to drink the 
entire contents. Subsequently, an additional 100 ml of 5% dextrose injection solution 
were added to the beaker and drank by the patient. On day 2 topotecan was 
administered at the same dose as a continuous 30 minute intravenous infusion. The 
5 mg vials of topotecan were reconstituted in 5% dextrose and the appropriate volume 
was then added to a volume of 50 ml of 5% dextrose. The drug was given at 
approximately the same time of day, between 8 am and 11 am. On both days of 
drug administration the patients were fasted from food for 4 hours prior to the time 
schedule for dosing. Fasting continued for a further 2 hours after drug administration 
on both days. Fluid intake was not restricted. 
Blood sample collection 
Serial heparinized blood samples (2.8 ml) were collected on both days of drug 
administration through an indwelling intravenous cannula, which was inserted in 
the arm contralateral to that which was used for the infusion. Blood samples were 
taken at 0,10,20,30,45 minutes and 1, 1.5, 2.5, 3.5,4.5,6.5 and 8.5 hours 
after start of drug administration. After collection, the blood samples were 
centrifuged immediately for 5 minutes at 3500 rpm. One ml of the plasma was 
immediately transferred to a polypropylene tube containing 4 ml of cold methanol 
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(-20°C) and mixed on a whirl mixer for 15 seconds. Subsequently, the mixture was 
centrifuged for 5 minutes at 3500 rpm and the clear supernatant was transferred 
to a clean polypropylene tube, closed tightly and stored immediately at -80°C until 
analysis. Analysis took place within one month. 
Chemicals 
All chemicals were obtained from Baker (Deventer, The Netherlands) and were of 
analytical grade or higher. 
Instruments 
The HPLC apparatus consisted of a pumping device model 6000A (Waters Assoc., 
Milford, MA, USA), an automated sample injection device model SP 8880 (Spectra 
Physics, Santa Clara, CA, USA), Perkin Elmer LS40 fluorescence detector (excitation 
wavelength: 381 nm, emission wavelength: 527 nm; Perkin Elmer, Norwalk, CT, 
USA) and a model SP-4290 data analysis system (Spectra Physics). Separation was 
achieved with a LiChrosorb RP-18 (particle size: 5 Jim) column (125x4 mm i.d., Merck, 
Darmstadt, Germany). 
Assay of topotecan and hydroxy-acid 
Topotecan and the hydroxy-acid were analyzed simultaneously with an automated 
reverse phase HPLC system and fluorescence detection as described (15), with 
modifications to lower the lower limit of quantitation (LLQ) (16). The LLQ was 0.1 
nglml for topotecan and as well as for the hydroxy-acid. Data were accepted if the 
deviation from the nominal value of the individual calibration samples and quality 
controls was < 15% (20% at the LLQ). 
Pharmacokinetic analysis 
Area under the plasma concentration-time curves (AUG) of topotecan and hydroxy-acid 
were calculated with compartmental and noncompartmental analysis using the Siphar 
software package release 4.0 (Siphar SIMED, Cedex, Creteil, France). The trapezoidal 
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method was used for the noncompartmental analysis. The AUG(t) was calculated 
up to the latest measured time point. The total AUG was calculated after extrapolation 
of the curve to infinity where appropriate using the terminal elimination rate constant 
k. The apparent bioavailability was calculated as the ratio of the AUG(t) after oral 
and i.v. administration. All concentration-time profiles were fitted using the extended 
least squares method (LSM) (17). The volume of distribution at steady state (V.,,,) 
and total plasma clearance (GL=Dose/AUG) were calculated after i.v. administration 
oftopotecan. The terminal half-life (t y,) was calculated after oral and i. v. administration 
as In2/k, 
Visual inspection of the concentration-time curves, the objective function and the 
Akaike information criterion (18) were applied to chose the optimal model for 
quantitation of the AUG, 
Statistical analysis 
The Pearson correlation coefficient was calculated between the ratio of the AUG(t) 
of the hydroxy-acid and topotecan after oral and Lv administration and between the 
ratio of the AUG(t) of the hydroxy-acid after oral and i.v, administration and the 
bioavailability, Two-sided paired and unpaired t-test were applied to determine any 
significant difference between the half-lives of topotecan and hydroxy-acid after oral 
and i.v, administration, The influence of the presence of liver metastases, concomitant 
medication on bioavailability and clearance were evaluated with the Mann-Whitney 
U test. The relationship between age and bioavailability and clearance was evaluated 
with the Pearson correlation coefficient and the Wilcoxon rank sum test. 
RESULTS 
Patients and treatment 
Twelve patients were included in the study (7 males and 5 females), The mean age 
was 62 ± 7,5 years (range 46-70). The median performance score was 1 (range 
0-2). Nine patients had metastatic colon cancer, 2 had small cell lung cancer and 
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1 ovarian cancer. Nine patients had documented liver metastases. Five patients did 
not use concomitant medication, two used a benzodiazepine, one used slow release 
morphine and diclofenac, one disopyramide, one alizapride and diclofenac, one atenolol 
and one atenolol, furosemide, nifedipine, naproxen, budesonide by inhalation, 
acetylsalicylic acid and nitroglycerine. All patients had been entered in phase II studies 
applying topotecan in a daily times 5 schedule with cycles repeated every 3 weeks. 
Oral administration of topotecan was without exception the first day of one of the 
5-day treatment cycles. Neither i.v. nor oral administration was associated with any 
significant acute side effect. The oral drinking solution was well tolerated. 
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Figure 1. 
Plasma concentration-time curve of topotecan and hydroxy-acid in a patient after 
oral and i.v. administration of 3.2 mg of topotecan . 
.. I.v. topotecan, • i.v. hydroxy-acid, t. oral topotecan, 0 oral hydroxy-acid, closed 
lines represent topotecan and the dotted lines the hydroxy-acid. 
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Pharmacokinetic analysis 
Representative plasma concentration-time curves of topotecan and hydroxy-acid 
after oral and i.v. administration are given in Fig. 1. Concentrations of topotecan 
lactone and hydroxy-acid assays were always undetectable on day two, prior to 
administration of the second dose. In only 6 out of 12 patients visual inspection of 
the obtained concentration-time profiles of topotecan after oral administration revealed 
a good fit of the measured plasma concentration-time points, applying extended LSM 
and one-, two-, or three compartments (the corresponding correlation coefficients 
[R] were> 0.97). All i.v. profiles of topotecan could be fitted well (R>0.97) applying 
LSM and the outlined models. In 10 patients the model using a 2-exponential decline 
of the concentration-time curve resulted in the highest correlation coefficent and 
lowest Akaike value. In 1 patient the model with a 3-exponential decline of the curve 
and in 1 other patient a l-exponential decline resulted in the beslfit. In most patients 
the curves of the hydroxy-acid could not be fitted properly using the extended LSM, 
assuming linear pharmacokinetics. The plasma concentration-time curves of the hydroxy-
acid were higher than of topotecan in all patients. The pharmacokinetic data are 
summarized in tables 1 and 2. 
After oral administration the percent extrapolated of the AUC in 8 patients was> 20%, 
therefore, the bioavailability was calculated using the ratio of AUC(t) instead of the 
AUC extrapolated to infinity. The mean ± SD of the AUC(t) of topotecan after oral 
administration was 15.18 ± 5.51 ng.h/ml (range 9.38-25.37 ng.h/ml). The AUC(t) 
of topotecan after Lv. administration was 49.87 ± 10.87 ng.h/ml (range 32.50-73.68 
ng.h/ml). The AUC of topotecan after Lv. administration was 61.02 ± 10.57 ng.h/ml 
(range 43.70-81 .08 ng.h/ml). The bioavailability was 30% ± 7.7 % (range 21 %-45%). 
The coefficient of variation (%CV) was 25.4%. If the curves would have been 
extrapolated to infinity, then the bioavailability would have been calculated as 32% 
± 11.5%. 
The median of the Tmax was 0.78 hours and the range 0.33-2.5 hours. 
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TOPOTECAN HYDROXY·ACID 
patient dose Tmax, 0 Cmax, 0 Cmax, IV AUC(t), 0 AUC(t), IV AUC, IV F AUC(t),O AUC(t),lV 
(no.) (mg) (hr) (ng/mll (ng/mll (ng.hr/mll (ng.hr/mll (ng.hr/mll (%) (ng.hr/mll (ng.hr/mll 
1 2.7 0.5 5.95 41.08 10.48 49.17 64.49 21 NE 59.86 
2 2.8 1.03 5.93 35.92 9.38 32.50 43.70 30 12.20 37.08 
3 3.2 0.33 5.16 43.86 10.85 42.37 56.34 25 15.10 60.72 
4 3.0 1.13 5.45 41.81 18.81 49.37 58.15 38 47.96 90.79 
5 2.7 0.52 5.71 33.40 11.25 37.96 46.64 30 NE 56.34 
6 3.0 0.55 7.14 47.18 12.75 55.09 69.62 23 29.30 100.83 
7 2.8 1.03 4.71 40.35 9.79 45.31 59.53 22 NE 65.07 
8 2.8 2.5 5.08 41.41 21.98 48.57 52.04 45 63.99 103.25 
9 3.1 0.5 6.48 41.21 12.46 55.00 66.00 23 19.22 57.70 
10 2.6 1.5 6.67 42.11 25.37 73.68 81.08 34 51.47 121.14 
11 2.8 1.0 5.38 25.35 21.56 62.31 70.14 35 19.01 63.77 
12 2.7 0.5 6.93 19.57 17.00 46.61 64.55 36 24.46 62.48 
MEAN 5.88 37.77 15.18 49.87 61.02 30 31.41 73.25 
SD 0.78 8.04 5.51 10.87 10.57 7.7 18.47 24.69 
o = oral, IV = intravenous, Dose = absolute dose (oral = i.v.j, Tmax = time to maximal plasma concentration, Cmax = maximal 
plasma concentration, AUC(t) = area under the curve up to the latest measured time point, AUC = area under the curve extrapolated 
to infinity, NE = not evaluated 
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Table 2. Mean pharmacokinetic data of topotecan lactone 
oral No. of i.v. No. of 
patients 
CI (ml/min) - 824 ± 117 N= 12 
(535 -1068) 
Vd" (I) - 128 ± 37.1 N= 12 
(86 - 231) 
t'hP (h) 2.43 ± 1.15 N= 10 2.40 ± 0.38 N= 12 
(1.02 - 3.20) (1.72 - 2.93) 
The half-life for the initial decline of the plasma concentration-time curve (t'h ,a) after 
i.v. administration was 0.186 ± 0.054 hours based on the data forthe 10 patients 
which were fitted with a bi-exponential model. 
The ratio of the AUC(t) of topotecan and the hydroxy-acid after oral administration 
was 0.63 ± 0.25 (n = 9) and after i.v. administration 0.72 ± 0.16. The correlation 
coefficient was 0.87 (p = 0.002). The ratio of the AUC(t) of the hydroxy-acid after 
oral and i.v. administration was 0.38 ± 0.12 (n = 9) which is of the same magnitude 
as the bioavailability of topotecan. The correlation coefficient between this ratio and 
the bioavailability was 0.84 (p = 0.004) 
There was no significant relationship between age or gender and the bioavailability. 
In addition, there was no significant relationship between the presence of liver 
metastases and the magnitude of the bioavailability. 
The Cmax of the hydroxy-acid after oral administration was 7.50 ± 2.57 ng/ml (range 
4.66-12.32 ng/ml) and after i.v. administration 18.97 ± 2.44 
ng/ml (range 15.35-24.12 ng/ml). The terminal t'h after oral administration was 2.82 
± 0.85 hours and after i.v. administration 3.22 ± 0.73 hours (not significantly 
different). 
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DISCUSSION 
The present study is the first to provide data on the systemic exposure of to po tee an 
after oral administration. Chronic administration of topotecan resulted in an enhanced 
antineoplastic activity (4,7,8,10·12). The concept of chronic administration is to 
some extent applied in a large number of phase II studies, which are currently in 
progress utilizing a daily times 5 intravenous infusion of 30 minutes or 21 day 
continuous infusion. Topotecan may show an even more pronounced antitumor response 
if the exposure duration is even further prolonged (7). It would increase the convenience 
for the patient substantially if the drug on a chronic treatment schedule could be 
taken orally. 
The apparent bioavailability was determined in 1 2 patients with various types of 
solid tumors. The bioavailability ranged from 21 to 45%. The term apparent 
bioavailability has been used because topotecan undergoes a reversible, pH dependent 
conversion to the hydroxy-acid at physiologic pH and the standard equation for the 
calculation of bioavailability no longer applies. The correct equations contain terms 
for the AUC of topotecan, and hydroxy-acid after i.v. administration of the hydroxy-acid 
itself. The standard equation for bioavailability, as used in this study, is a function 
not only of dose and input rate, but of conversion clearance. The accuracy of the 
apparent bioavailability data will depend, to a large extent, on the magnitude of the 
conversion clearance, for which no in vivo data on topotecan are available. Even 
though at physiologic pH the formation of the hydroxy-acid is the predominant reaction, 
experiments on camptothecin in the rat have shown that the lactone can be formed 
following the i.v. administration of the hydroxy-acid (19). As camptothecin and 
topotecan have the same basic ring structure, it is highly likely that topotecan could 
also be formed following administration of the topotecan hydroxy-acid. 
The bioavailability was determined after oral administration on day 1 and i.v. 
administration on day 2. This strategy was followed to deviate as little as possible 
from the phase II daily times 5 schedule which has documented therapeutic activity 
in several tumor types. The approach is justified because there is no carryover of 
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topotecan into the second treatment period. In addition, topotecan is not metabolised 
and therefore cannot induce its own elimination. Plasma samples were collected up 
to 8 hours after oral administration. This was slightly too short to extrapolate the 
AUG up to infinity. The sampling time was determined based on preclinical data on 
the oral administration in dogs and on the elimination pharmacokinetics after Lv. 
administration in man. The bioavailability after oral administration in dogs was 35.7 
± 16.3% (unpublished data), which is close to the result obtained in humans. The 
calculation of the bioavailability using the AUG calculated to infinity resulted in only 
a marginally higher value of 32% instead of 30%. Apparently, the applied ratio of 
AUG(t) gives a good estimation of the bioavailability. 
The n" ,p in the patient with the highest bioavailability of 45 % was 1.8 h after i.v. 
and 3.2 h after oral administration. This difference was relatively large in comparison 
to the data obtained in the other patients. This patient had a large tumor in the upper 
part of the abdomen. It cannot be excluded that this extensive tumor mass has 
influenced the rate of passage of topotecan through the gastrointestinal tract and 
thereby the magnitude of the absorption. The Tmax of this patient was 2.5 h, which 
is very delayed compared to the range of the other 11 patients (0.33-1.5 h). The 
%GV olthe AUG(t) after oral administration was 36.3 % and after Lv. administration 
21.8%. Hence oral administration increased the interpatient difference in systemic 
exposure markedly. It has to be elucidated in follow-up studies whether this variation 
has clinical implications. In addition, the intra patient variability needs to be determined 
in future studies. 
The %GV olthe plasma clearance of to po tee an after Lv. administration was 18.8%. 
The range of the data was of the same order as reported by Rowinsky at al. (4) and 
Verweij at al. (8). 
No relationships were found between patient characteristics as age, gender, 
performance score and the bioavailability. In addition, the presence of liver metastases 
or concomitant drugs did not seem to be related to the magnitude of the bioavailability. 
The ratio of topotecan and hydroxy-acid was of the same order after oral and Lv. 
administration. There would appear only two reasonable explanations for the observed 
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data: either topotecan is poorly absorbed from the gastrointestinal tract or that 
topotecan is well absorbed but that a large part of the dose is converted 
presystemically, in the gut, into the hydroxy-acid which is itself not absorbed to any 
appreciable extent. The good water solubility of topotecan coupled with the rapid 
absorption, would suggest that the second explanation can best describe the data 
obtained in this study. There is no evidence for the formation of other metabolites 
which may explain the observed data. 
The bioavailability of topotecan after oral administration illustrates significant systemic 
exposure to the drug, which may enable chronic oral treatment. 
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SUMMARY 
Background and purpose: T opotecan is a specific inhibitor of tapa isomerase I. Recently 
bioavailability of an oral formulation of approximately 30% with limited variability 
was reported. We conducted a phase I and pharmacokinetic study of the oral 
formulation of topotecan to characterize the maximum-tolerated dose (MTD), toxicities, 
pharmacokinetics and antitumor effects in patients with refractory malignancies. 
Patients and methods: Patients were treated with oral topotecan given twice daily 
for 21-days, cycles repeated every 28-days. In subsequent cohorts the dose was 
escalated from 0.15 to 0.6 mg/m2 b.i.d. Pharmacokinetics were performed on day 
1 and 8 of the first course using a validated high liquid performance chromatographic 
assay and noncompartmental pharmacokinetic methods. 
Results: 31 patients entered the study, one patient was not evaluable for toxicity 
and response as therapy was prematurely interrupted on request of the patient without 
experiencing toxicity. 30 patients received a total of 59 courses. The dose limiting 
toxicity was reached at a dose of 0.6 mg/m2 b.i.d. and consisted of diarrhea, starting 
subacutely at a median onset on day 15 (range 12-20) and resolving after a median 
of 8 days (range 7-16). Other toxicities were mild, including leucopenia, 
thrombocytopenia, nausea and vomiting. The maximum-tolerated dose was 0.5 mg/m2 
b.i.d. No responses were observed. Pharmacokinetics revealed a substantial variation 
of the AUC(t) of topotecan and ring-opened product hydroxy-acid. A significant 
correlation was observed between the percentage of decrease in WBC versus the 
AUC(t) of topotecan (R=0.75) which was modelled by a sigmoidal Em" function. 
Conclusions: The dose-limiting toxicity in this phase I study for chronic oral topotecan 
for 21-days was diarrhea. The recommended dose for phase II studies is 0.5 mg/m2 
b.i.d. 
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INTRODUCTION 
T opotecan, (s)-9-dimethylaminomethyl-1 O-hydroxycamptothecin, is a watersoluble 
semisynthetic analogue of camptothecin (CPT) (1). like camptothecin, topotecan 
is a specific inhibitor of topoisomerase I. Topoisomerase I is a nuclear enzyme that 
resolves topological problems of the supercoiled DNA. This is achieved by forming 
a covalent adduct between topoisomerase I and the DNA, termed the cleavable 
complex. This catalytic intermediate creates single strand breaks, allowing the DNA 
molecule to rotate around the intact DNA strand at the cleavage site leading to a 
relaxation of the DNA molecule and in this way replication, transcription and other 
DNA functions can proceed. These enzyme-bridged breaks are then resealed by 
topoisomerase I. Topoisomerase I inhibitors interfere with the breakage-reunion process 
by stabilizing the cleavable complexes thereby preventing the resealing of single breaks 
in the presence of the drug. Cytotoxicity is specific to the S-phase of the cell cycle 
because the double strand breaks that occur during this phase are more difficult to 
repair in the absence of the drug. So, in the absence of DNA replication or in case 
of short exposure topoisomerase I inhibitors produce little or no cytotoxicity (2,3). 
Moreover, preclinical studies using human colony-forming units in vitro, have indicated 
that prolonged exposure demonstrates more efficacy and has a greater therapeutic 
index (4,5). 
The feasibility of this concept of prolonged exposure in humans was reported by 
Hochster et al. (6), in a phase I study using a 21-days continuous infusion repeated 
every 28-days. Responses were seen in tumor types that are usually considered 
chemotherapy resistant. In pretreated patients the infusion was tolerated at a dose 
of 0.53 mg/m'/day. For patients with no prior treatment the tolerated dose was 0.7 
mg/m'/day. The dose limiting toxicity was myelosuppression with thrombocytopenia 
being somewhat more profound compared to neutropenia. 
Recently reported results reveal a 32-44% bioavailability of oral topotecan (7,8), 
and thus oral administration might be a more simple and convenient method to achieve 
prolonged exposure. In view of the relatively short half life of topotecan and in order 
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to mimic as good as possible the continuous infusion schedule, the oral formulation 
was initially tested at a bidaily schedule. We performed a phase I study on oral 
topotecan given twice daily for 21-days repeated every 28 days. 
PATIENTS AND METHODS 
Patient selection 
Patients with a histologically confirmed diagnosis of a malignant solid tumor refractory 
to standard forms of therapy were eligible. Other eligibility criteria included: age between 
18· 75 years; an Eastern Cooperative Oncology Group (ECOG) performance status 
:;; 2; an estimated life expectancy of ~ 12 weeks; no previous anticancer therapy 
for ~ 4 weeks (6 weeks for nitrosoureas or mitomycin C); adequate hematopoietic 
(WBC ~ 4x1 0'/1 and platelets ~ 1 00x1 0'11), hepatic (bilirubin within normal limits, 
AST, ALT andlor alkaline phosphatase:;; 2x normal), and renal (serum creatinine 
:;; 132.6 pmolll) function. Specific exclusion criteria included: active peptic ulcer 
or any gastrointestinal condition which could alter absorption or motility; patients 
taking H,-antagonists or proton pump inhibitors. All patients gave written informed 
consent before entry in the study. 
Treatment and dose escalation 
Based on the data of Hochster et al (6). using topotecan as a 21·days continuous 
infusion with a MTD of 0.53 mglm'lday and given a bioavailability of 32% of oral 
administration of topotecan (7) the starting dose for the 21-days oral administration 
was set at 0.15 mglm' given twice daily. Courses were to be repeated every 28 
days as tolerated. Dose escalations were based on the prior dose level toxicity. For 
example if no toxicity was seen in the prior dose, :;; 100% dose escalation was 
allowed. However, if toxicity was seen, a dose escalation of 25-50% (which was 
determined by the worst significant toxicity) was prescribed. At least four patients 
were entered at each dose level. The maximum tolerated dose (MTD) was defined 
as one dose level below the dose that induced dose limiting toxicities (DL T), which 
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were defined as CTC grade 4 hematologic toxicity andlor nonhematologic toxicity 
;;, CTC grade 3 in more than 2/6 patients. If neutropenia grade 4, thrombocytopenia 
;;, grade 3 andlor non-hematologic toxicity;;, grade 3 occurred during treatment 
days, the topotecan administration was stopped immediately. Intra patient dose escala-
tion was not performed. 
Topotecan was supplied as capsules containing topotecan HCL, equivalent to either 
0.2 mg or 0.3 mg of the anhydrous free base. Capsules had to be stored at a tempera-
ture between 2-8 degrees celsius. Capsules were taken with an interval of 12 hours 
with a glass of water at least 10 minutes before meals, preferably on an empty 
stomach. 
Patients were treated as outpatients. 
Treatment assessment 
Prior to therapy, complete medical history was taken and a physical examination 
was performed. A complete blood count (CBC) including WBC differential, and serum 
biochemistry involving sodium, potassium, chloride, bicarbonate, calcium, phosphorus, 
magnesium, creatinine, urea, uric acid, bilirubin, AST, AL T, alkaline phosphatase, 
total protein and albumin were performed, as were urinalysis, ECG and chest X-ray. 
Weekly evaluations included history, physical examination, toxicity assessment 
according to the CTC criteria and serum chemistries. CBC were determined twice 
weekly. Tumor measurements were performed after every two courses and evaluated 
according to the WHO criteria for response. Patients were taken off protocol in case 
of disease progression. 
Pharmacokinetics 
For pharmacokinetic analysis, whole blood samples (2.8 ml) in heparinized tubes 
were collected from an indwelling Lv canula, prior to dosing, 15, 30, 45 minutes 
and 1, 1.5,2.5, 3.5, 4.5, 8.5 and 12 hours after administration of the drug on day 
1 and 8 of the first course. The samples were immediately prepared and analyzed 
according to the method as described by Loos et al. (9). The lower limit of quantitation 
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(LLQ) was 0.1 ng/ml for topotecan as well as for the, hydroxy-acid. Area under the 
plasma concentration-time curves (AUG) of topotecan and hydroxy-acid were calculated 
by noncompartmental analysis (linear-logarithmic trapezoidal method). The AUG(t) 
was calculated up to the last measured time point "t", because in most cases the 
extrapolated part was;" 20 % of the total AUG. The terminal half-life was calculated 
as In2/k, where k is the elimination rate constant (h"). The AUG(t) was fitted to 
observed percentage decrease in WBG and ANG using the sigmoidal Em" model (10). 
For all calculations the Siphar software package release 4.0 (Siphar SIMED, Gedex, 
Grete ii, France) was used. For statistical analysis, linear regression analysis was 
employed to evaluate relationships between dose and dose/m' and AUG(t), and Pearson 
correlation coefficients were calculated. Spearman rank correlation coefficients were 
calculated between AUG(t) and the GTG-grade leuco- and thrombocytopenia and 
diarrhea. For statistical analysis statgraphics was employed (Manngistics, MD, USA). 
RESULTS 
A total of 31 patients entered the study. Patient characteristics are given in table 
1. All patients were eligible but one patient with colorectal cancer was considered 
not evaluable for toxicity and response because upon request of the patient he was 
taken off protocol on day 10 of the first course without any notable toxicity at that 
time. Therefore 30 patients were evaluable for toxicity and response. The majority 
of patients were either asymptomatic or only mildly symptomatic (i.e EGOG performance 
status 0-1). All patients, except one, had received priortherapy. The most common 
tumor type was colorectal cancer. The total number of evaluable courses was 59. 
The median number of courses per patient was 2 (1-10). Dose levels studied were 
0.15,0.3,0.4,0.5 and 0.6 mg/m' b.i.d., resulting in total daily doses of 0.3, 0.6, 
0.8, 1.0 and 1.2 mg/m' respectively. 
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Table 1: Patient characteristics 
No. patients entered 
No. patients evaluable 
Age 
Sex 
median 
range 
female 
male 
Performance status 
median 
range 
Tumor types 
colorectal 
oropharynx 
ovarian 
lung (non-small cell) 
melanoma 
breast 
carcinoma unknown primary 
soft tissue sarcoma 
gastric 
kidney 
cervix 
Prior treatment 
radiotherapy 
chemotherapy 
radio- and chemotherapy 
no prior therapy 
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No. of patients 
31 
30 
55 
33-73 
18 
13 
1 
0-2 
12 
4 
3 
2 
2 
2 
2 
1 
1 
1 
1 
2 
14 
14 
1 
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Hematologic toxicity 
Overall, the hematologic toxicities were relatively mild (table 2). with leucopenia 
and thrombocytopenia mainly occurring (if at all) during the third and fourth week 
of the course and being shortlasting. The next treatment course had to be postponed 
due to prolonged myelosuppression in 2 courses in patients experiencing grade 3-4 
leucopenia. Grade 3-4 leucopenia was observed in 6 of the 59 courses (10.2%), 
in 1 patient being complicated by neutropenic fever. In 3 courses (5%) grade 3-4 
thrombocytopenia was noted, 2 in conjunction with leucopenia. 
Table 2: Hematologic toxicity (worst per patient) 
Dose No. Leucocytes Granulocytes Platelets 
(mg/m2/b.i.d) pts 
eTe grade 
I I 1 2 3 4 1 2 3 4 1 2 3 4 
0.15 4 0 1 0 0 0 0 0 1 0 0 0 0 
0.3 8 1 1 1 0 0 0 1 0 0 0 1 0 
0.4 8 0 1 0 0 1 0 0 0 0 0 0 0 
0.5 8 0 2 2 2 2 2 0 2 0 0 0 2 
0.6 3 0 1 1 0 0 2 0 0 2 0 0 0 
Non-hematologic toxicity 
Diarrhea was the dose-limiting toxicity (DL T) of topotecan at a dose of 0.6 mg/m2-
b.i.d. in this schedule (table 3). The onset of severe diarrhea was abruptly (figure 
1) with a median day of onset being on day 15 (range 12-20). 
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Table 3: Non-hematological toxicity (worst per patient) 
Dose No. Nausea Vomiting Diarrhea 
(mg/m2/b.i.d) pts 
eTe grade 
1 2 3 4 1 2 3 4 1 2 3 4 
0.15 4 2 0 0 0 3 0 0 0 0 0 1 0 
0.3 8 4 0 0 0 1 0 0 0 3 0 0 0 
0.4 8 4 0 0 0 0 0 0 0 1 1 0 1 
0.5 8 3 4 0 0 2 0 0 0 4 1 0 2 
0.6 3 1 1 0 0 1 0 0 0 0 0 0 3 
The diarrhea lasted for median duration of 8 days (range 7-16 days) and resulted 
in dehydration requiring hospitalization for parenteral fluid and electrolyte therapy 
in all 3 patients at the 0.6 mg/m2 b.i.d. dose level. One patient showed a different 
pattern of diarrhea. Two days after initiating topotecan therapy the patient developed 
diarrhea which gradually became worse. On day 17 the treatment was stopped 
according to protocol and the diarrhea resolved in 7 days. According to the protocol, 
topotecan administration was stopped after developing severe diarrhea. Vigorous 
administration of loperamide for treatment of diarrhea was ineffective in reducing 
its severity. Stool cultures and examination for fecalleucocytes were negative in 
these patients. Endoscopy was performed in two patients, revealing a mild non-specific 
colitis. 
Prophylactic anti-emetics were not routinely used in the study. Mild intermittent nausea 
and vomiting (grade 1-2) was observed in respectively 32% and 11.8%of the given 
courses and could be circumvented with standard anti-emetics. 
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Alopecia occurred in 2 patients. No other toxicities were seen. There was no stomatitis, 
hypotension, liver or renal toxicity. 
Figure 1: 
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Graph showing the severity of diarrhea in two different patients at the dose of 0.6 
mg/m' b.i.d. At the top (patient A) the frequency and at the bottom (patient B) the 
volume is depicted in relation to the duration (days) of diarrhea. 
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Figure 2: 
Graph showing representative AUCs of topotecan and hydroxy-acid on day 1 and 
8. 
Pharmacokinetics and dynamics 
Pharmacokinetics were performed in 14 patients, well distributed over all dose levels. 
A representative plasma-concentration-time curve of topotecan and the hydroxy-acid 
on day 1 and 8 is shown in figure 2. After oral administration the percent of AUC 
which had to be extrapolated was more than 20% in most patients. Therefore, the 
AUC(t) was calculated, where "t" denotes the latest measured point. The 
pharmacokinetic data are summarized in table 4. 
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Table 4. Pharmacokinetics 
Topotecan Day 1 Hydroxy-acid Day 1 T opotecan Day 8 Hydroxy-acid Day 8 
Dose level Dose AUC(t) t1/2 AUC(t) t1/2 AUC(t) n/2 AUC(t) t1l2 
mg/m2 mg ng.hr/ml h ng.hr/ml h ng.hr/ml h ng.hr/ml h 
0.15 0.40 0.81 1.36 0.76 2.97 1.32 2.56 2.72 2.85 
0.15 0.30 1.55 3.22 5.03 4.34 2.80 4.49 7.49 5.93 
0.30 0.50 6.20 3.39 9.70 6.29 8.12 2.90 11.80 2.97 
0.30 0.70 1.41 1.28 1.27 2.36 1.30 1.49 1.44 3.91 
0.30 0.60 5.29 3.45 9.66 4.49 7.17 3.55 13.84 2.80 
0.40 0.70 1.71 2.06 2.27 2.62 5.04 2.78 6.64 2.62 
0.40 0.80 4.61 1.98 5.72 2.71 6.87 2.63 9.32 2.43 
0.50 0.90 5.86 0.99 10.12 3.63 7.24 2.70 15.40 4.44 
0.50 0.90 5.75 2.49 9.08 4.75 6.95 3.76 11.84 6.47 
0.50 1.10 1.63 1.80 3.53 3.24 3.67 2.14 6.65 2.69 
0.50 1.10 2.47 1.52 7.58 3.55 3.99 2.94 9.20 3.17 
0.60 1.00 4.93 1.68 6.67 3.29 7.66 2.97 9.41 3.88 
0.60 1.30 8.54 3.09 13.00 3.13 10.72 4.81 NQ NQ 
0.60 1.10 4.91 4.61 8.18 3.22 8.20 NQ 10.30 1.54 
mean. 0.81 3.98 2.35 6.61 3.61 5.79 3.06 8.93 3.52 
SO 0.30 2.35 1.05 3.68 1.04 2.82 0.91 4.00 1.40 
%CV 36.3% 59.1% 44.7% 55.6% 28.9% 46.8% 29.6% 44.6% 39.9% 
NQ not quantificable, %CV coefficient of variation 
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The AUC(t) of topotecan and hydroxy-acid showed substantial variation. High correlation 
was found between the ratio AUC(t) of top ate can and the AUC(t) of hydroxy-acid 
on day 1 and 8 (R = 0.96). The AUC(t) of topotecan and hydroxy-acid were 
consistently higher on day 8 compared to day 1 (figure 3). The mean AUC(t) ± SD 
of topotecan on day 8 was 5.79 ± 2.82 ng.hr/ml and was 26% higher than the 
AUC(t) on day 1 which was 3.98 ± 2.35 ng.hr/ml. The interpatient variability (%CV) 
in AUC(t) of topotecan on day 1 and 8 were 59.1 % and 46.8%, respectively. 
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Relationship between the AUC(t) of topotecan on day 1 and day 8 of course 1. 
20 
The correlation between dose and AUC(t) of topotecan was relatively low (R = 0.44). 
There was no significant relationship between the dose of topotecan and the occurrence 
of leucopenia or thrombocytopenia (R = 0.41, p = O. 15). 
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There was a significant correlation between the AUG(t) oftopotecan and percentage 
of decrease in WBG (R = 0.75, P = 0.003). The latter data could be fitted best using 
a sigmoidal Em" model (figure 4). There also was a significant correlation between 
AUG(t) and the GTG-grade of thrombocytopenia (R=0.59, p=0.04). 
Finally, while there was a trend towards a significant relationship between the GTG-
grade of diarrhea and the administered dose (R = 0.51, P = 0.08), there was no 
correlation between AUG(t) and the GTG-grade of diarrhea. 
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Figure 4: 
The percentage decrease in WBG versus AUG(t) of topotecan during course 1. The 
curve is fit to a sigmoidal Em" model. 
Responses 
Objective responses have not been observed. Disease stabilization of 11 months 
was noted in one patient with colorectal cancer at the dose of 0.3 mg/m' b.i.d. 
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DISCUSSION 
The topoisomerase I inhibitors continue to rapidly move through clinical development 
with their unique mechanism of action and their activity against a variety of 
malignancies. Topotecan has been extensively studied utilizing different intravenous 
dosing schedules, revealing shortlasting non-cumulative neutropenia and/or 
thrombocytopenia as the dose-limiting toxicity (DL T) (11,1 2). 
The present study was based on the promising results of prolonged exposure and 
the oral bioavailabilityof topotecan.ln vitro experiments with topotecan using short-
term 1-hour exposure at a concentration of 1.0 and 10 Jlg/ml showed responses 
in respectively 10% and 25%. In contrast, using continuous exposure at concentrations 
of 0.1 and 1.0Jlg/ml responses were seen in 34% and 76% respectively (5). Prolonged 
exposure experiments with topotecan against xenografts derived from adult and 
childhood solid tumors also revealed significant activity against several human cancers 
(rhabdomyosarcoma and colon cancer) without any toxicity and its efficacy may 
be schedule dependent (4). The oral bioavailability was determined at 30% ± 7.7% 
in a study using topotecan at a dose of 1 .5 mg/m2, with moderate inter patient variation 
(21-45%) (7). In another study the bioavailability waS determined utilizing the maximum 
tolerated dose (MTD) of the oral (14 mg/m2) and intravenous (17.5 mg/m2) routes 
of administration, revealing a bioavailability 0.1 44% (8). In contrast to the intravenous 
routes, the dose-limiting toxicity (DL T) for the twice daily oral administration for 21-days 
was diarrhea at the dose of 0.6 mg/m2 b.i.d. Mostly, the diarrhea started in the third 
week of drug administration. It waS always self-limiting after a median duration of 
8 days (7 -16). At the time the diarrhea occurred, vigorous administration of loperamide 
WaS ineffective in reducing this toxicity. Treatment consisted of supportive care with 
the administration of fluids and electrolytes. Diagnostic evaluation (i.e. stool cultures, 
biopsies) in several of these patients failed to find a pathogenetic mechanism for 
this diarrhea. The pattern and severity of this diarrhea resembles the severe diarrhea 
seen in patients treated with irinotecan, another topoisomerase I inhibitor, particularly 
when the latter is used in intermittent dosing schedules employing higher single doses. 
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With irinotecan grade 3-4 delayed diarrhea is observed in approximately 20% of the 
patients (11-16). Irinotecan is converted by endogenous carboxylesterase to its active 
metabolite SN-38. The development of diarrhea might be associated with the amount 
of carboxyl esterase activity in the intestinal mucosa, liver and plasma (17). As diarrhea 
has never been reported as a major side-effect with the intravenous route of topotecan 
administration it is speculated that the cause of diarrhea with chronic oral administration 
is a local effect of topotecan and/or the excipient on the intestinal mucosa. The CTC-
grade of diarrhea appeared to be correlated with the administered dose. 
Nausea and vomiting, were intermittent and mild, never exceeding grade 2 toxicity, 
resembling the gastrointestinal toxicities noted with longterm continuous infusion 
of topotecan (11,18). 
Hematological toxicity was relatively mild, grade 3-4 hematological toxicity was 
observed in 10.2% of the courses and consisted of leucopenia which in 2/6 courses 
occurred in conjunction with thrombocytopenia grade 3-4. In comparison, the DL T 
in the phase I study using a 21-days continuous infusion was hematologic with thrombo-
cytopenia being somewhat more profound than leucopenia (6). In addition, myelotoxicity 
was the single relevant side effect in a phase" study using long term continuous 
infusion of topotecan at a dose of 0.5 mg/m'/day in patients with untreated metastatic 
colorectal cancer. Moreover, that study revealed that the myelosuppression was 
prolonged, cumulative and coincided by a marked inhibition of the erythropoiesis 
( 18). 
Pharmacokinetic data from the present study revealed a substantial interpatient 
variability in the AUC(t) and the AUC(t) on day 8 was consistently higher, indicating 
some cumulation of the drug. 
Nevertheless, in this study a significant correlation was found between the systemic 
exposure and the % decrease in the leucocytes (figure 4). 
Topoisomerase I inhibitors are highly S-phase specific, and in vitro, cytotoxicity is 
a function of exposure time to the drug above some critical concentration (4,5,20). 
Recently, Hochster et al. (19) have shown that with continuous infusion of topotecan 
in humans, progressive depletion of topoisomerase I levels is observed until the end 
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of the second week. Pursing such a less protracted exposure-time in using the oral 
administration might enable the use of higher doses per day resulting in higher 
concentrations. Moreover, this way the troublesome diarrhea may possibly be 
circumvented, as in the present study it mainly started in the third week of treatment. 
In conclusion, in this phase I study with oral administration of topotecan given twice 
daily for 21-days the MTD was reached at a daily dose of 0.5 mg/m2 , with diarrhea 
being the DL T. The concept of prolonged exposure via oral administration remains 
attractive, but from the experience in the present study, it is possible that shortening 
the exposure time might result in better tolerance with a better chance to see antitumor 
activity. Based on that studies are planned to test 5 and 10 days of oral administration. 
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Summary 
SUMMARY 
This thesis describes clinical and pharmacological studies on the topoisomerase I 
inhibitor topotecan, with a focus on the efficacy of the daily x5 intravenous schedule 
in patients with colorectal and ovarian cancer. In addition, the concept of prolonged 
exposure was studied. 
In chapter 1 an introduction is presented about the synthetic chemistry efforts, which 
have led to the development of the watersoluble analogue topotecan, which is a 
derivative of the parent drug camptothecin; an extract from the Asian tree Camptotheca 
acuminata. 
Chapter 2 gives an overview of the two main topoisomerase I inhibitors under clinical 
investigation: topotecan and irinotecan (CPT-11). Both drugs, like camptothecin, 
undergo a pH dependent reversible hydrolysis of the active lactone (closed form) 
to the inactive hydroxy-acid (open form). The plasma clearance of topotecan is 
biexponential with a half-life of approximately 3 hours. The volume of distribution 
at steady state is large (25-190 I) and the major route of excretion is renal. The 
pharmacokinetics of irinotecan are complex since irinotecan is a prodrug that is rapidly 
converted in vivo to its active metabolite SN-38. The half-lives of both lactone forms 
of irinotecan and SN-38 are 7-8 hrs on average. Hepatic glucuronidation and biliary 
excretion is the major route of elimination for both compounds. In preclinical models, 
topotecan and irinotecan show impressive antitumor activity. In phase I studies, the 
dose-limiting toxicities were of brief duration, i.e. non-cumulative neutropenia with 
or without mild thrombocytopenia for topotecan, and for irinotecan neutropenia and 
diarrhea. 
In the initial phase I studies of topotecan it was shown that a daily x 5 schedule 
had the most convincing evidence of antitumor activity. This had led us to clinical 
studies of the daily x5 schedule of topotecan. 
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In chapter 3 the phase II study results are presented on the daily x 5 schedule in 
patients with metastatic or locally irresectable colorectal cancer. Partial responses 
were obtained in 4 (7%) of the 57 evaluable patients. The treatment was very well 
tolerated. The major side effect was neutropenia (91 %), being grade 3-4 in 79% 
of the courses, without any neutropenic infection due to the short duration of 
neutropenia. It is concluded that topotecan in this schedule has minor activity as 
a single agent in colorectal cancer. 
In chapter 4 the phase II study results are detailed of the daily x5 schedule as second-
line treatment in patients with epithelial ovarian cancer, who developed recurrent 
or progressive disease after one line of platinum combination therapy. Ninety-two 
patients were evaluable for response. The overall response rate was 16% (1 GR, 
14 PRs). When calculated according to platinum refractoriness, platinum resistance 
and platinum sensitivity the response rates were 6%, 18% and 27%. The major toxicity 
was neutropenia grade 3-4 in 69%, with 4% neutropenic infections. It is concluded 
that topotecan in a daily x5 schedule is an active regimen with a favourable toxicity 
profile as second-line therapy in ovarian cancer. 
In chapter 5 pharmacokinetics and pharmacodynamics of topotecan in a daily x5 
schedule in phase II studies are described using a limited sampling procedure, in which 
AUG of topotecan and hydroxy-acid were calculated by plasma concentration 
determination of only one blood sample taken 2 hours after the infusion. Samples 
were obtained of 36 patients in 136 treatment days. The mean AUG of topotecan 
was 8.74 pM.min/day and the mean AUG of hydroxy-acid was 11.5 pM.min/day, 
with a large interpatientvariability. Intrapatient variability during treatment days was 
minor, which indicates that no drug accumulation occurs. The intrapatientvariability 
between the courses was also small. The relationship between the AUG of topotecan 
and the percentage of decrease in the absolute neutrophil count in these phase II 
studies strongly resembled the relationship as observed in a previous phase I study. 
It is concluded that despite the large interpatient pharmacokinetic variability, the 
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usefulness of regular drug monitoring in this schedule is marginal because the pharmaco-
dynamic variability was relatively small. 
Chapter 6. In preclinical studies it has been shown that topoisomerase I inhibitors 
exhibit better efficacy and have a greater therapeutic index with prolonged continuous 
exposure to the drug. Here, the results are presented of a phase II study of topotecan 
administered as a 21-days continuous infusion at a dose of 0.5-0.6 mg/m2/day to 
patients with locally advanced, irresectable or metastatic colorectal cancer. The overall 
response rate was 10% (1 CR, 3PRs). The major side effect was prolonged and 
cumulative myelosuppression including a marked inhibition of the erythropoiesis. 
Pharmacokinetics revealed a significant correlation (R ~0.54) between the GTC-grade 
of leucopenia and the steady state plasma concentration of topotecan. It is concluded 
that this schedule, which is inconvenient for patients, exerts only modest activity 
in patients with colorectal cancer. 
Because of the inconvenience of continuous infusion, and the high oral bioavailability 
reported in animals, the oral formulation of topotecan was studied in man. 
In chapter 7 the oral bioavailability of topoteca~ is described. The oral bioavailability 
of topotecan was calculated as the ratio between the AUG(t), in which "t" denotes 
the latest measured point of an oral dose of 1.5 mg/m2 given as a drinking solution 
and the AUG(t) of an intravenous dose of 1.5 mg/m2 given as a 30 minute infusion. 
The oral bioavailability was 30% ± 7.7%. It is concluded that the oral bioavailability 
of topotecan results in adequate systemic exposure with modest interpatient variability. 
In chapter 8 a phase I and pharmacological study is presented of topotecan administered 
in capsules twice daily for 21 days to patients with solid tumors. Thirty patients were 
evaluable for toxicity and response. The dose-limiting toxicity was reached at a dose 
of 0.6 mg/m2 b.Ld. and consisted of diarrhea starting median on day 15 (range 12-20), 
which was self-limiting after a median of 8 days (range 7 -16). Other toxicities were 
mild and included leuco- and thrombocytopenia, nausea and vomiting. The maximum 
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tolerated dose and recommended dose for phase II studies is 0.5 mg/m2 b.i.d .. Pharma-
cokinetics revealed substantial variation of the AUC(t) of topotecan. Significant 
correlation was seen between the percentage of decrease in WBC and the AUC(t) 
of topotecan. One study with continuous infusion of topotecan in humans has shown 
a progressive depletion of topoisomerase I levels until the end of the second week. 
Consequently, the optimal concentration-time relationship of topotecan might be 
less than 3 weeks. For the oral administration a shorter than 3 weeks exposure-time 
might enable higher doses per day resulting in higher plasma concentrations. 
Final conclusions 
Topoisomerase I inhibitors are a new class of drugs in medical oncology. 
From the results of phase I studies with topotecan the daily x5 schedule was initially 
selected for phase II studies. We and others have shown that this dosing schedule 
is effective and has a favourable toxicity profile as second-line treatment in patients 
with ovarian cancer and small cell lung cancer. 
Although this thesis does not contain efficacy data of prolonged treatment with 
topotecan, based on theoretical considerations and on preclinical data the concept 
of prolonged exposure with topotecan in the treatment of solid tumors remains 
attractive, especially as a chronic oral administration. Therefore, further studies including 
the subject of the optimal concentration-time relationship are warranted. 
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SAMENVATTING 
Dit proefschrift bevat klinisch en farmacologisch onderzoek met de topoisomerase 
I remmertopotecan. De onderzoeken waren vooral gericht op de anti-tumor effecten 
van 5 dagelijkse intraveneuze toedieningen een maal per 3 weken bij patienten met 
colorectale en ovariumcarcinomen. Tevens is het concept van verlengde expositieduur 
bestudeerd. 
Hoofdstuk 1 is een inleiding over de ontwikkeling van de semisynthetische 
topoisomerase I remmer topotecan uit de moederstof camptothecine. 
In hoofdsluk 2 wordl een overzicht gegeven van de klinisch belangrijksle lopoisomerase 
I remmers; lopotecan en irinotecan (CPT-11). Evenals camptothecine ondergaan beide 
stoffen een pH afhankelijke reversibele hydrolyse van de actieve lacton (gesloten) 
vorm naar de inactieve hydroxy (open) vorm. De plasma klaring van topotecan is 
biexponentieel met een halfwaarde tijd van circa 3 uur. Het verdelingsvolume is groot 
en de excretie vindl hoofdzakelijk plaats via de nieren. De farmacokinetiek van irinotecan 
is complex doordat irinotecan een prod rug is die in vivo snel wordt omgezel in de 
actieve melaboliet SN-38. De halfwaarde lijd van zowel irinotecan en SN-38 is langer 
dan die van topotecan. Biliaire excretie is voor zowel irinotecan als SN-38 de 
belangrijksle eliminatie roule. In preklinische modellen verlonen zowel topotecan 
als irinotecan indrukwekkende anti-tumor activiteil. De dosis limiterende toxiciteit 
in tase I studies met topotecan was kortdurende, nie! cumulatieve neutropenia soms 
gepaard gaand mel milde trombocytopenie. Voor irinotecan was de dosis limiterende 
toxiciteit neutropenie en diarree. In de eerste fase I studies met topotecan werd de 
meest uitgesproken anti-tumor activiteit gezien met het schema waarbij op 5 
achtereenvolgende dagen een kort infuus werd gegeven. 
In hoofdstuk 3 worden de resultaten beschreven van de fase II studie met het 5-daagse 
schema bij patienten met een gemetastaseerd of inoperabel colorectaal carcinoom. 
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Er werden 4 (7%) partiele responsen gezien bij 57 evalueerbare patienten. Topotecan 
werd zeer goed verdragen. De belangrijkste bijwerking was neutropenie (91 %); CTC-
graad 3-4 in 79% van de kuren. Door de korte duur van de neutropenie traden geen 
infectieuze complicaties op. Dit toedienings-schema van topotecan heelt slechts 
beperkte activiteit bij colorectale carcinomen. 
In hoofdstuk 4 worden de resultaten vermeld van de fase II studie met het 5-daagse 
schema als tweedelijns behandeling bij patienten met een epitheliaal ovarium carcinoom, 
die progressie of een recidief hadden na eerstelijns behandeling met platina bevattende 
chemotherapie. Twee-en-negentig patienten waren evalueerbaar voor respons. Het 
respons percentage was 16% (1 CR, 14 PRs). Wanneer de patienten werden 
gegroepeerd als platina refractair, platina resistent en platina sensitief, waren de 
respectievelijke respons percentages 6%,18% en 27%. De belangrijkste bijwerking 
was neutropenie; CTC-graad 3-4 in 69% van de kuren. Vier procent van de kuren 
ging gepaard met infectieuze complicaties. Dit 5-daagse schema met topotecan is 
actief als tweede lijns behandeling van ovarium kanker. 
In hoofdstuk 5 worden de farmacokinetische en farmacodynamische resultaten uit 
fase II studies met 5-daagse topotecan schema bepaald volgens de "limited sampling 
methode" geanalyseerd. Bij deze methode worden de AUC van topotecan en hydroxy 
vorm berekend door bepaling van slechts een bloedmonster 2 uur na de infusie. Er 
werden monsters genomen van 36 patienten op 136 behandeldagen. De gemiddelde 
AUC van topotecan was 8,74 pM.min/dag en de gemiddelde AUC van de hydroxy 
vorm was 11,5 pM.min/dag, met een grote interpatient variatie. De intrapatient 
variabiliteit was gering. Dit suggereert dat er geen cumulatie van topotecan is gedurende 
de 5 behandelingsdagen. Ook was de intrapatient variabiliteit tijdens de kuren gering. 
De relatie tussen de AUC van topotecan en de procentuele daling van de neutrofielen 
in deze fase II studies kwam goed overeen met de relatie in de fase I studies met 
het 5-daagse topotecan schema. Ondanks de grote farmacokinetische interpatient 
variabiliteit is de waarde van regelmatige farmacokinetische meting en beperkt is gezien 
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de geringe farmacodynamische variabiliteit. 
Hoofdstuk 6. In preklinische modellen zijn er aanwijzingen dattopoisomerase I remmers 
effectiever zijn en een grotere therapeutische index hebben in geval van een verlengde 
continue expositie. Hier worden de resultaten weergegeven van de fase II studie 
met topotecan gedurende 21 dagen in een dagelijkse dosis van 0,5-0,6 mg/m2 door 
middel van een continue inlusie via een draagbare pomp. De patienten hadden een 
in opera bel 01 gemetastaseerd colorectaal carcinoom. Het bereikte respons percentage 
was 10% (1 CR, 3 PRs). De belangrijkste bijwerking was langdurige en cumulatieve 
myelosuppressie, met een opvallende remming van de erythropoiese. Er bestond 
een signilicante correlatie (R =0,54) tussen de mate van leucopenie en de "steady-state" 
plasma concentratie van topotecan. Dit schema heelt geringe therapeutische activiteit 
bij colorectal carcinomen en is belastend voor patienten. 
Bij orale toediening van topotecan aan proeldieren bleek de biologische beschikbaarheid 
groot te zijn. Daarom hebben wij de orale toediening van topotecan ook bij patienten 
bestudeerd. 
In hoofdstuk 7 wordt de biologische beschikbaarheid van oraal toegediend topotecan 
beschreven. De biologische beschikbaarheid werd berekend als de ratio tussen de 
AUC(t), waar "t" staat voor het laatst gemeten tijdstip, van oraal topotecan (1,5 
mg/m2) toegediend als een drinkbare oplossing en de AUC(t) van een intraveneuze 
dosis (1,5 mg/m2) toegediend in 30 minuten. De biologische beschikbaarheid was 
30% ± 7,7%. Deze resultaten tonen dat orale toediening van topotecan leidt tot 
adequate systemische expositie met beperkte interpatient variatie. Deze bevinding 
vormde het argument voor een studie met continue orale toediening. 
In hooldstuk 8 wordt een fase I studie gepresenteerd waarin topotecan, in capsule 
vorm, tweemaal per dag gedurende 21 dagen aan patienten met solide tumoren werd 
toegediend. Dertig patienten waren evaluabel voor toxiciteit en respons. De dosis-limite-
rende toxiciteit werd bereikt bij een dosis van 0,6 mg/m2 2dd en bestond uitdiarree, 
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welke mediaan optrad op de dag 15 (spreiding 12-20) en mediaan 8 dagen later 
spontaan verdween (spreiding 7-16). Andere bijwerkingen waren leuco- en 
trombocytopenie, misselijkheid en bra ken. De maximaal tolereerbare dosis en 
geadviseerde dosis voor lase II studies is 0,5 mg/m2 2dd. De AUC(t) van topotecan 
en de hydroxy vorm lieten een substantiiile interpatient variatie zien. Er bestond een 
signilicante correlatie tussen de procentuele daling van de leucocyten en de AUC(t) 
van topotecan. In een studie met continue infusie van topotecan werd tot ongeveer 
twee weken een progressieve depletie van topoisomerase I spiegels geobserveerd. 
Daarom is de optimale concentratie-tijds relatie van topotecan mogelijk korter is dan 
21 dagen. Voor orale toediening van topotecan kan een expositieduur korter dan 
3 weken mogelijk resulteren in een hogere dagdosis en hogere plasma concentraties. 
T opoisomerase I remmers zijn een nieuwe klasse cytostatica. Gezien de resultaten 
in lase I studies met het 5-daagse topotecan schema werd dit schema geselecteerd 
voor lase II studies. Wij en andere onderzoekers hebben aangetoond dat dit schema 
effectiel is als tweedelijns therapie bij patiiinten met ovarium carcinoom en kleincellig 
bronchus carcinoom, met relatiel weinig bijwerkingen. 
Ondanks dat in dit proelschrift geen effectiviteit is gezien met verlenging van expositie-
duur van topotecan, blijft op basis van zowel theoretische als preklinische gegevens 
het concept van langdurige expositie blijlt attractiel, zeker de chronische orale 
toediening. Daarom zijn verdere studies ge"indiceerd om de optima Ie concentratie-tijds 
relatie van topotecan te bepalen. 
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van de Dr. Daniel den Hoed Kliniek (opleider: W. Sizool Prof. dr. B. Lowenberg). In 
maart 1993 werd hij geregistreerd als internist. In de periode van januari 1993 tot 
januari 1995 was hij werkzaam als junior-internist op de afdeling interne oncologie 
van de Dr. Daniel den Hoed Kliniek, waar de studies werden verricht die resulteerden 
in dit proefschrift (hoofd: Prof. dr. G. Stoter). Sedertjanuari 1995 is hij geregistreerd 
voor het aandachtsgebied interne oncologie en werkzaam als internist in het 
streekziekenhuis Walcheren te Vlissingen. 
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